Introduction {#s1}
============

The extracellular calcium-sensing receptor (CaSR) is responsible for the maintenance of a stable blood Ca^2+^ level ([@bib6]; [@bib25]). It senses fluctuations in the circulating Ca^2+^ concentration and controls Ca^2+^ homeostasis by (1) modulating the production of parathyroid hormone in parathyroid glands, and (2) regulating the reabsorption of Ca^2+^ in kidney and bone ([@bib8]). Abnormal function of CaSR is associated with Ca^2+^ homeostatic disorders ([@bib7]; [@bib24]; [@bib70]). Loss-of-function mutations in CaSR lead to potentially fatal neonatal severe primary hyperparathyroidism, while gain-of-function mutations cause autosomal dominant hypocalcemia ([@bib24]; [@bib70]). CaSR also plays important roles in biological processes unrelated to Ca^2+^ balance, including fetal development ([@bib57]), nutrient sensing ([@bib12]), and regulation of neuronal excitability ([@bib61]).

The functional diversity of CaSR results from its ability to activate multiple signaling pathways through G~q/11~, G~i/o~, G~12/13~ and G~s~ proteins ([@bib15]; [@bib25]; [@bib36]), and to respond to a variety of ligands ([@bib36]; [@bib62]). The general consensus is that the principal agonist of CaSR is extracellular Ca^2+^ ([@bib25]). Other orthosteric agonists include various divalent and trivalent cations, polyamines and cationic polypeptides ([@bib36]; [@bib62]).

CaSR function can be regulated by endogenous and synthetic allosteric modulators, extracellular pH and ionic strength ([@bib28]; [@bib50], [@bib51]; [@bib62]). Aromatic and aliphatic L-amino acids such as L-Phe and L-Trp increase the sensitivity of CaSR toward Ca^2+^ ([@bib14]) and are considered as positive allosteric modulators of the receptor ([@bib62]). Previous studies have also demonstrated that L-amino acids can activate the receptor provided that Ca^2+^ concentration is above a threshold ([@bib13]; [@bib14]; [@bib56]; [@bib77]). For this reason, L-amino acids have been called allosteric activators ([@bib13]). Finally, it has been proposed that Ca^2+^ ions and amino acids may act as co-agonists of the receptor ([@bib14]; [@bib77]). However, this view has not been widely accepted.

CaSR is a class C G-protein-coupled receptor (GPCR). Within this family, CaSR and metabotropic glutamate receptors (mGluRs) function as disulfide-linked homodimers ([@bib3]; [@bib47]; [@bib55]; [@bib22]; [@bib71]; [@bib80]), while GABA~B~ and taste receptors are obligatory heterodimers ([@bib29]; [@bib32]; [@bib33]; [@bib43], [@bib44]; [@bib45]; [@bib72]). Ligand binding to CaSR takes place within a large extracellular Venus Flytrap (VFT) module that consists of two domains (LB1 and LB2) ([@bib5]; [@bib23]; [@bib41]). In addition, CaSR contains a cysteine-rich (CR) domain that connects the VFT module to the transmembrane region ([@bib23]). This CR region is present in all class C GPCRs except GABA~B~ receptor and is required for receptor activation ([@bib21]; [@bib26]; [@bib27]). However, the activation mechanism of CaSR remains unknown.

Structural information for class C GPCRs is available for the extracellular domains (ECD) of mGluRs ([@bib34]; [@bib42]; [@bib67]) and GABA~B~ receptor ([@bib18], [@bib19]), as well as the transmembrane domains of mGluRs ([@bib16]; [@bib74]). Here, we present the first crystal structures of the entire extracellular domain of human CaSR in two different functional states. These structures reveal novel binding sites for Ca^2+^, PO~4~^3-^ and L-Trp, identify L-Trp as an agonist of the receptor, and demonstrate that these ions and amino acids collectively control the function of CaSR.

Results {#s2}
=======

Structure of CaSR ECD homodimer {#s2-1}
-------------------------------

The ECD of human CaSR was secreted from baculovirus-infected insect cells as a disulfide-tethered homodimer ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). It contains 11 potential N-linked glycosylation sites. Disruption of three of the glycosylation sites did not alter CaSR signaling ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Formation of well-diffracting crystals required partial deglycosylation of the receptor through mutation and enzymatic digestion. We obtained two different forms of CaSR ECD crystals. Form I was crystallized in the absence and presence of 2 mM Ca^2+^, and form II in the presence of 10 mM L-Trp and 10 mM Ca^2+^ ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.13662.003Table 1.Data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.003](10.7554/eLife.13662.003)10.7554/eLife.13662.004Table 1---source data 1.Statistics for anomalous data collection.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.004](10.7554/eLife.13662.004)10.7554/eLife.13662.005Table 1---source data 2.Data collection and refinement statistics for endogenous ligand-bound CaSR ECD.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.005](10.7554/eLife.13662.005)Functional stateInactive\
(2 mM Ca^2+^)Active\
(10 mM Ca^2+^, 10 mM L-Trp)CrystalForm IForm II**Data collection**Space groupF222C2Wavelength (Å)0.97921.7712Cell dimensions* a, b, c* (Å)126.3, 150.2, 214.6107.7, 127.5, 146.8 α, β, γ (°)90.0, 90.0, 90.090.0, 108.7, 90.0Resolution (Å)88.1 - 3.1 (3.6 - 3.1)139.0 - 2.6 (2.9 - 2.6)*R*~sym~ or *R*~merge~0.051 (0.702)0.043 (0.575)*I* / σ*I*21.3 (2.1)22.1 (2.3)Completeness (%)99.9 (100.0)98.0 (97.1)Redundancy6.6 (6.8)6.9 (6.8)CC~1/2~ (%)100.0 (93.1)99.9 (96.9)**Refinement**Resolution (Å)107.2 - 3.137.5 - 2.6No. of reflections16,74748,839*R*~work~ / *R*~free~ (%)22.2 / 23.921.1 / 22.2No. of atoms Protein45648454 Ligand (Trp)-30 Cation (Ca^2+^)18 Anion15 (SO~4~^2-^)20 (PO~4~^3-^) Sugar9870 Water43331*B*-factors (Å^2^) Protein110.468.3 Ligand-39.9 Cation (Ca^2+^)105.496.3 Anion102.1 (SO~4~^2-^)61.0 (PO~4~^3-^) Sugar152.980.4 Water76.953.8R.m.s. deviations Bond lengths (Å)0.0080.009 Bond angles (°)1.151.14[^1][^2]

In both CaSR ECD structures, the two protomers interact in a side-by-side fashion while facing opposite directions ([Figure 1](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Each CaSR ECD protomer consists of three domains, LB1, LB2 and CR. The two lobe-shaped domains LB1 and LB2 form a VFT module similar to that of mGluRs ([@bib34]; [@bib42]; [@bib67]) and GABA~B~ receptor ([@bib18], [@bib19]). The relative orientation between the LB2 and CR domains is fixed through an interdomain disulfide linkage (C236-C561), and the CR domain is positioned to amplify and transmit the conformational variations within the VFT module.10.7554/eLife.13662.006Figure 1.Crystal structures of human CaSR ECD.(**A**) Inactive-state structure of CaSR ECD homodimer in the presence of 2 mM Ca^2+^. (**B**) Active-state structure of CaSR ECD homodimer in the presence of 10 mM Ca^2+^ and 10 mM L-Trp. Each structure is shown in cartoon (front view) or surface (side view) representations that are related by a 90°-rotation about the vertical axis. Each protomer is colored according to its individual domains (LB1, light blue; LB2, blue; CR, purple). The various ligands (L-Trp, Ca^2+^, PO~4~^3-^, SO~4~^2-^) are displayed as space-filling models. Observed carbohydrates are shown as ball-and-stick models in gray. Disulfide bridges are in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.006](10.7554/eLife.13662.006)10.7554/eLife.13662.007Figure 1---figure supplement 1.Purification of the CaSR ECD homodimer.(**A**) Superdex-200 size exclusion chromatography of secreted wild-type (wt) CaSR ECD. (**B**) SDS gel of wt-CaSR ECD before and after Endo H digestion under reducing condition. ([**C**]{.smallcaps}) Superdex-200 size exclusion chromatography of secreted CaSR ECD mutant carrying three glycosylation-site mutations (N386Q, S402N and N468Q). (**D**) SDS gel of purified CaSR ECD mutant from (**C**) under reducing (+DTT) and non-reducing (-DTT) conditions. (**E**) Dose-dependent Ca^2+^-stimulated IP accumulation in cells expressing wild-type or mutant CaSR. The full-length CaSR contains either two (N386Q, S402N) or three (N386Q, S402N and N468Q) glycosylation-site mutations.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.007](10.7554/eLife.13662.007)10.7554/eLife.13662.008Figure 1---figure supplement 2.Different conformational states of CaSR ECD.(**A**) Cartoon representation of the inactive (form I) CaSR ECD crystal structure. (**B**) Cartoon representation of the active (form II) CaSR ECD crystal structure. Each homodimer structure is shown in five views: front (center), top (top), bottom (bottom), and two side (center left and right) views. Each protomer is colored according to its individual domains (LB1, light blue; LB2, blue; CR, purple). The various ligands (L-Trp, Ca^2+^, PO~4~^3-^, SO~4~^2-^) are displayed as space-filling models. Observed carbohydrates are shown as ball-and-stick models in gray. Disulfide bridges are in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.008](10.7554/eLife.13662.008)

Form I crystal structure of CaSR ECD represents the inactive configuration since the VFT modules of both protomers are in the open conformation associated with the resting state (open-open), and the interdomain cleft is empty. In addition, each protomer structure contains one Ca^2+^ ion and three SO~4~^2-^ ions ([Figure 1A](#fig1){ref-type="fig"}).

In the form II crystal structure, both protomers of CaSR ECD have the closed conformation associated with agonist binding (closed-closed). Surprisingly, the ligand-binding cleft of each protomer is solely occupied by an L-Trp molecule. Ca^2+^ is bound at four novel sites in the CaSR ECD structure, including one at the homodimer interface. Each CaSR ECD molecule also contains two PO~4~^3-^ ions ([Figure 1B](#fig1){ref-type="fig"}).

Agonist binding induces large conformational changes within the CaSR ECD homodimer. First, the VFT module of each protomer undergoes domain closure. Alignment based on the LB1 domains showed that the LB2 domains of inactive and active structures are related by a 29° rotation ([Figure 2A](#fig2){ref-type="fig"}). Second, the LB2 domains of the two protomers approach each other, resulting in an expansion of the homodimer interactions involving LB2 domains. Third, the CR domains of the two subunits interact to form a large homodimer interface that is unique to the active state. The CR domains are brought into close contact by the motion involving LB2 since the two domains are rigidly associated within each subunit. Finally, the structural reorganization of CR domains reduces the distance between the C-termini of the two subunits from 83 Å to 23 Å ([Figure 2B,C](#fig2){ref-type="fig"}). This CR domain movement may cause reorientation of the transmembrane domains during receptor activation.10.7554/eLife.13662.009Figure 2.Agonist-induced conformational changes.(**A**) Superposition of the inactive (orange) and active (blue) CaSR ECD structures based on the LB1 domain of one protomer (front view, left; side view, right). Green line is the axis of rotation that relates the LB2 domains of the superimposed protomers (rotation χ = 29°, screw translation τ~χ~ = −2.2 Å). (**B**, **C**) Surface representation of inactive (**B**) and active (**C**) structures in front (top) and bottom (bottom) views. Distance between C-termini of the two subunits (yellow) is marked by dashed line for each homodimer.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.009](10.7554/eLife.13662.009)

Common protomer-protomer interactions {#s2-2}
-------------------------------------

The inactive structure of CaSR ECD shows that subunit association in the resting state is primarily mediated by the LB1 domains ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This dimer interface is largely conserved in the active structure, indicating that the LB1-LB1 interaction mostly serves to faciliate dimerization between receptor subunits ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).10.7554/eLife.13662.010Figure 3.Homodimer interface.(**A**) Cα trace of inactive structure with elements involved in homodimer formation highlighted by cartoons. The interface is divided into three regions I, II, and IV. Site II is further separated into two symmetrical parts II_a and II_b. Specific contacts at each interface region are shown in surrounding panels. Dashed lines indicate hydrogen bonds. (**B**) Cα trace of active structure showing elements involved in homodimer formation. The interface is divided into six regions, I, II, III, IV, V, and VI. Specific contacts at the interface areas III, IV, V, and VI are shown in surrounding panels. For both structures, the domains involved in dimerization at each interface region are: I: LB1-LB1; II: LB1-LB1; III: LB2-LB1; IV: LB2-LB2; V: LB2-CR; VI: CR-CR. (**C**) Dose-dependent Ca^2+^-stimulated IP accumulation in cells transiently expressing wild-type (wt) or mutant CaSR. Naturally occurring inactivating mutations L159P, R172G, D215G, R227L, R551K, and G557E are located at the homodimer interface. The single mutation W458A was designed based on structure to affect receptor homodimerization.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.010](10.7554/eLife.13662.010)10.7554/eLife.13662.011Figure 3---figure supplement 1.Homodimer interface.(**A**, **B**) Cα traces of inactive (**A**) and active (**B**) CaSR ECD structures. Each structure is presented in three views: top (left), front (center) and side (right). Structural elements involved in homodimer formation are highlighted by cartoons. (**C**, **D**) A detailed view of the structural elements at the homodimer interface region I of inactive (**C**) and active (**D**) CaSR ECD structures. For each structure, the angle between the D-helices of the two subunits is shown and is used to represent dimer orientation at this interface. (**E**, **F**) Cα traces of inactive (**E**; PDB code: 4MQE) and active (**F**; PDB code: 4MS4) GABA~B~ receptor (GABA~B~R) ECD structures. (**G**, **H**) A detailed view of the structural elements at the heterodimer interface of inactive (**G**) and active (**H**) GABA~B~R ECD structures. For each structure, the angle between the C-helices of the two subunits is shown. (**I**, **J**) Cα traces of inactive (**I**; PDB code: 1EWT) and active (**J**; PDB code: 1EWK) mGluR1 VFT module structures. ([**K**]{.smallcaps}, **L**) A detailed view of the structural elements at the homodimer interface of inactive (**G**) and active (**H**) mGluR1 VFT structures. For each structure, the angle between the C-helices of the two subunits is shown. Panels (**E**) -- (**L**) were adapted from Supplementary [Figure 13](#fig13){ref-type="fig"} of ([@bib18]).**DOI:** [http://dx.doi.org/10.7554/eLife.13662.011](10.7554/eLife.13662.011)10.7554/eLife.13662.012Figure 3---figure supplement 2.Homodimer interface.Specific contacts at the interface areas I, II_a, and II_b of the active CaSR ECD structure.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.012](10.7554/eLife.13662.012)

The LB1-LB1 dimer interface buries over 3800 Å^2^ of solvent-accessible surface area, and can be divided into two regions. Site I is located at the center of LB1 domain and is flanked on either side by the two symmetric parts of site II ([Figure 3A,B](#fig3){ref-type="fig"}).

Site I is formed by two central helices (B, D) of each protomer ([Figure 3A,B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). A dimer interface formed by the same structural elements is also observed in mGluR and GABA~B~ structures ([@bib18]; [@bib34]; [@bib42]; [@bib67]). For mGluRs, transition between the resting and active configurations causes a 70°-rotation in the LB1-LB1 homodimer interface ([@bib34]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). For both CaSR and GABA~B~ receptors ([@bib18]), however, agonist binding only induces a small 5°-rotation in the orientation of this interface, and the LB1-LB1 dimer interface is largely conserved throughout the activation process ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

The dimer interactions at site I of CaSR are predominantly hydrophobic and involve tightly packed leucine and phenylalanine residues (L112, L156, L159, and F160). The disease-causing mutation L159P renders the receptor less sensitive to Ca^2+^ ([@bib20]; [@bib24]) ([Figure 3C](#fig3){ref-type="fig"}). In addition, site I features an inter-subunit disulfide bridge located at the tip of helix C.

Site II is unique to the CaSR ECD structures. It involves an arm-like long loop stretched out from one subunit to reach its binding partner ([Figure 3A,B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The dimer interactions at site II include hydrogen bonds and hydrophobic contacts. Several disease-causing mutations are located at this interface (S53P, P55L, and Y161C) ([@bib24]). Substitution of a deeply buried interfacial residue W458 with alanine also decreased the potency of Ca^2+^ ([Figure 3C](#fig3){ref-type="fig"}). These observations indicate that formation of a stable homodimer is important for CaSR function.

Agonist-induced homodimer interface {#s2-3}
-----------------------------------

Agonist binding causes an expansion of the dimer interactions involving LB2 domain. In the inactive homodimer, only minimal contacts occur between the LB2 domains ([Figure 3A](#fig3){ref-type="fig"}). In the active state, LB2 of one protomer interacts with all three domains of a second protomer ([Figure 3B](#fig3){ref-type="fig"}). These contacts are predominantly hydrophilic, and bury 1000 Å^2^ of solvent accessible surface area.

LB2 mediates dimer interactions primarily through a central helix (G) that transverses the domain ([Figure 3B](#fig3){ref-type="fig"}). First, the top of helix G contacts LB1 domain of the opposing subunit through two symmetric salt bridges between D215 and R172 (site III). Second, the LB2-LB2 contacts involve the midsection of helix G, and feature a hydrogen bond between R227 and S240, and water-mediated contacts by E224 (site IV). Finally, LB2 interacts with the CR domain of a second subunit through a Ca^2+^ ion (site V). This Ca^2+^ ion bridges the end of helix G in LB2 with a loop in CR domain. An abundance of disease-related mutations are found at these dimer interaction sites, including (1) R172G and D215G at site III, (2) R227L and R227Q at site IV, and (3) G557E at site V ([@bib24]). All these mutations disrupt agonist-dependent dimer contacts, and decreased agonist efficacy ([@bib22]; [@bib24]; [@bib75]) ([Figure 3C](#fig3){ref-type="fig"}).

Agonist binding also induces the formation of a novel homodimer interface between the CR domains that covers approximately 1200 Å^2^ of solvent accessible surface area (site VI) ([Figure 3B](#fig3){ref-type="fig"}). The CR-CR interactions are mediated by two β-strands and their connecting loop from each subunit. Key contacts include two cross-subunit hydrogen bonds (T560, E558), hydrophobic contacts (I554, P569), and electrostatic interactions (R551). Among these, R551K is a known disease-causing mutation that reduced the receptor response ([@bib24]; [@bib66]) ([Figure 3C](#fig3){ref-type="fig"}).

Amino acid recognition {#s2-4}
----------------------

In the active structure, the amino acid L-Trp is bound at the interdomain cleft of the VFT module, in agreement with previous mutational data ([@bib40]; [@bib41]; [@bib78], [@bib79]) ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). L-Trp facilitates extracellular domain closure of CaSR by contacting both LB1 and LB2 domains of the VFT module ([Figure 4B,C](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The interactions between CaSR ECD and L-Trp are primarily mediated by hydrogen bonds. (1) The carboxylic acid group of L-Trp forms hydrogen bonds through both oxygen atoms with LB1 residues S147, A168, and S170. (2) The backbone nitrogen of L-Trp is hydrogen-bonded to A168 and S170 of LB1 domain. (3) The indole nitrogen of L-Trp forms two hydrogen bonds with E297 of LB2 domain. (4) L-Trp is engaged in hydrophobic contacts with both LB1 and LB2 residues including W70, T145, Y218, and A298. The extensive contacts between backbone atoms of L-Trp and the receptor suggest that other amino acids may bind to CaSR in a similar fashion to induce domain closure.10.7554/eLife.13662.013Figure 4.L-Trp recognition by CaSR ECD.(**A**) Molecular surface of a L-Trp-bound CaSR ECD protomer in the active structure. L-Trp is displayed as a space-filling model. (**B**) Specific contacts between CaSR ECD (gray) and L-Trp (yellow). Mesh represents the final 2Fo-Fc electron density map contoured at 1σ. Hydrogen bonds are represented by dashed lines. (**C**) Schematic diagram of the interactions between CaSR ECD and bound L-Trp. Selected contacts are highlighted; hydrogen bonds, dashed lines; hydrophobic contacts, wiggled lines. (**D**) Dose-response curves of nonradioactive L-Trp inhibiting \[^3^H\]-L-Trp binding to CaSR ECD in the presence of 0 mM or 2 mM Ca^2+^. (**E**--**F**) Dose-dependent L-Trp-induced intracellular Ca^2+^ mobilization at various extracellular Ca^2+^ concentrations in cells stably expressing CaSR. (**E**) Effect of increments of L-Trp (final concentrations: 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10, 20 mM) in the presence of 1.5 mM extracellular Ca^2+^. The experiments were followed by an exposure to 0.5 mM extracellular Ca^2+^ to demonstrate reversibility of the L-Trp-induced intracellular Ca^2+^ oscillation, and a later exposure to 8 mM extracellular Ca^2+^ to demonstrate the maximal response. (**F**) Integrated response curves of L-Trp at 0.5, 1.5, and 2.5 mM Ca^2+^. Intracellular Ca^2+^ responses are presented in integrated response units (IRUs, F340/F380.min). (**G**) Effect of L-Trp on Ca^2+^-stimulated intracellular Ca^2+^ mobilization in cells transiently expressing wt CaSR. (**H**--**L**) Dose-dependent Ca^2+^-stimulated IP accumulation in cells transiently expressing wild-type or mutant CaSR. Naturally-occurring inactivating mutations Y218S and E297K are located at the L-Trp binding site. The single mutations T145I, S147A, and S170A were designed based on structure to disrupt L-Trp recognition.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.013](10.7554/eLife.13662.013)10.7554/eLife.13662.014Figure 4---figure supplement 1.L-Trp recognition by CaSR ECD.(**A**) Molecular surface of L-Trp-bound CaSR ECD homodimer. L-Trp is displayed as a space filling model. (**B**, **C**) Specific contacts between CaSR ECD (gray) and L-Trp (yellow) within each protomer of the active structure. Mesh represents the final 2Fo-Fc electron density map contoured at 1σ. Hydrogen bonds are represented by black dashed lines. (**D**) Superposition of the L-Trp-binding site in CaSR (gray) and Glu-binding site in mGluR1 (cyan). Agonist-binding residues that are located at the same locations of the two receptor structures are highlighted.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.014](10.7554/eLife.13662.014)10.7554/eLife.13662.015Figure 4---figure supplement 2.Endogenous ligand of CaSR.(A) Active-state structure of CaSR ECD homodimer showing unexplained electron density at the interdomain crevice of each protomer when crystals of CaSR ECD were grown in the presence of 10 mM Ca^2+^ and absence of any additional L-amino acids. (B, C) Close-up view of the region surrounding the extra density. Mesh represents a 2Fo-Fc electron density map contoured at 1σ.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.015](10.7554/eLife.13662.015)

We measured the direct interaction between L-Trp and CaSR ECD by scintillation proximity assay (SPA) ([@bib49]) ([Figure 4D](#fig4){ref-type="fig"}). CaSR ECD exhibited binding of \[^3^H\]-L-Trp in the absence and presence of Ca^2+^. Isotope dilution of \[^3^H\]-L-Trp with nonradioactive L-Trp led to a displacement of \[^3^H\]-L-Trp in a concentration-dependent manner. The addition of 2 mM Ca^2+^ increased the amount of L-Trp bound to CaSR ECD at any given concentration, suggesting that extracellular Ca^2+^ enhances L-Trp binding, possibly by affecting the L-Trp-binding affinity and kinetics of CaSR. The half-maximal inhibitory concentration of L-Trp (IC~50~, concentration at which 50% displacement of \[^3^H\]-L-Trp was observed) was approximately 2 mM regardless of whether the experiment was performed in the absence (2.11 ± 0.72 mM) or presence (2.04 ± 0.10 mM) of 2 mM Ca^2+^. Nevertheless, the binding affinity of L-Trp to CaSR ECD with and without Ca^2+^ may still differ as it depends on the concentration and binding affinity of the radiolabeled ligand. Further studies are needed to characterize the effect of Ca^2+^ on L-amino acid binding at the orthosteric agonist site of CaSR.

We found that L-Trp directly stimulated intracellular Ca^2+^ mobilization through CaSR ([Figure 4E,F](#fig4){ref-type="fig"}), in agreement with previous findings ([@bib13], [@bib14]; [@bib56]; [@bib77]). L-Trp-induced CaSR activation required the presence of extracellular Ca^2+^ above a threshold level of 0.5 mM. The effect of L-Trp on CaSR was concentration-dependent, with an apparent half-maximal effective concentration (EC~50~) of 0.12 ± 0.06 mM when extracellular Ca^2+^ was present at 2.5 mM. The efficacy and potency of L-Trp decreased at lower concentrations of Ca^2+^ that are within the physiological range (L-Trp EC~50~ = 0.75 ± 0.51 mM at 1.5 mM Ca^2+^), consistent with previous proposal that multiple amino acids need to act in concert to control the function of CaSR ([@bib14], [@bib13]).

L-Trp is also important for Ca^2+^-stimulated CaSR response. First, L-Trp elevated the sensitivity of CaSR toward extracellular Ca^2+^ ([@bib14]) ([Figure 4G](#fig4){ref-type="fig"}). The presence of 10 mM L-Trp lowered the EC~50~ of extracellular Ca^2+^ by about 30%. Second, the residues involved in L-Trp binding are crucial for Ca^2+^-dependent receptor activation. Previous and current studies demonstrate that each of the individual mutations S147A, S170A, Y218A, and E297K abolishes Ca^2+^-induced receptor response ([@bib63]; [@bib79]) ([Figure 4H--L](#fig4){ref-type="fig"}). Furthermore, E297K is a naturally occurring inactivating mutation that can lead to life-threatening hyperparathyroidism ([@bib2]; [@bib24]; [@bib48]). These observations suggest that the binding of an amino acid is required for extracellular Ca^2+^-sensing by CaSR.

Ca^2+^-binding {#s2-5}
--------------

We identified four distinct Ca^2+^-binding sites within each protomer of the active structure using anomalous difference maps, and named these sites 1 through 4 (or 1′-4' in the second protomer) ([Figure 5A,B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Table 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The inactive structure revealed electron density at site 2 that is consistent with a bound Ca^2+^ ion ([Figure 5C,D](#fig5){ref-type="fig"}). None of the Ca^2+^-binding sites observed in the CaSR ECD structures has been reported previously.10.7554/eLife.13662.016Figure 5.Ca^2+^-binding sites.(**A**) Active-state structure showing peaks in anomalous difference Fourier map (magenta mesh; 3σ contour level) that correspond to bound Ca^2+^ ions. Sites are labeled 1--4 or 1\'-4\' for each protomer. (**B**) Specific contacts between CaSR ECD and each bound Ca^2+^ ion within one protomer of the active structure. Anomalous difference Fourier map (magenta): sites 1--3, 6σ; site 4, 4.5σ. Fo-Fc difference map (blue): sites 1--3, 4.5σ; site 4, 2.5σ. Distances between Ca^2+^ and oxygen atoms (dashed lines) are within 3.0 Å. Dashed lines between water and protein atoms are hydrogen bonds. (**C**) Inactive-state structure showing peaks in anomalous difference Fourier map (magenta mesh; 3σ) at Ca^2+^-binding sites 2 and 2\'. (**D**) Specific contacts between CaSR ECD and bound Ca^2+^ ion within one protomer of the inactive structure. Anomalous difference Fourier map (magenta): 5σ. Fo-Fc difference map (blue): 4.5σ.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.016](10.7554/eLife.13662.016)10.7554/eLife.13662.017Figure 5---figure supplement 1.Ca^2+^-binding sites in the active homodimer.(**A**) Active-state structure of CaSR ECD showing peaks in anomalous difference Fourier map (magenta mesh; 3σ contour level) that correspond to bound Ca^2+^ ions. Sites are labeled 1--4 or 1\'-4\' for each protomer. (**B**, **C**) Specific contacts between CaSR ECD and each bound Ca^2+^ ion within both protomers of the active structure. Anomalous difference Fourier map (magenta mesh): sites 1--3, 6σ; site 4, 4.5σ. Fo-Fc difference map (blue mesh): sites 1--3, 4.5σ; site 4, 2.5σ. The distances between Ca^2+^ and oxygen atoms (dashed lines) are within 3.0 Å. Dashed lines between water and protein atoms are hydrogen bonds. (**D**) Comparison of inactive (red) and active (blue) structures in the region of each Ca^2+^-binding site.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.017](10.7554/eLife.13662.017)

Site 1 is located in a loop region at the top of LB1 domain ([Figure 5A,B](#fig5){ref-type="fig"}). The bound Ca^2+^ ion is primarily coordinated by backbone carbonyl oxygen atoms of I81, S84, L87, and L88 (site 1′). The structural configuration of site 1 is similar in the inactive and active structures even though it is only occupied in the active state ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The disease-causing mutation I81M ([@bib24]) is located at site 1, and it abolished Ca^2+^-dependent receptor response, possibly by disrupting a tightly packed hydrophobic patch adjacent to Ca^2+^-binding site 1 ([Figure 6A,B](#fig6){ref-type="fig"}). This implies that the local conformation of this loop region is important for receptor function, and the Ca^2+^ ion stabilizes the observed conformation in the active state.10.7554/eLife.13662.018Figure 6.Mutational analysis of Ca^2+^-binding sites.(**A**, **B**) Dose-dependent Ca^2+^-stimulated IP accumulation (**A**) and intracellular Ca^2+^ mobilization (**B**) in cells transiently expressing wt or mutant CaSR. Naturally occurring inactivating mutations I81M and T100I are located at various Ca^2+^-binding sites. The single mutation N102I was designed based on structure to interfere with Ca^2+^-binding.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.018](10.7554/eLife.13662.018)

The inactive and active structures share a common Ca^2+^-binding mode at site 2, suggesting that the bound Ca^2+^ is an integral part of the CaSR structure ([Figure 5A--D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Site 2 is positioned directly above the interdomain crevice in LB1 domain, and it abuts the L-Trp binding site in the cleft. The Ca^2+^ ion is coordinated by the hydroxyl group of T100 in both states, and by the carboxyl group of N102 through a water molecule in the active structure. In addition, T145, another residue lining the site, forms part of the L-Trp binding cleft in the active state. Therefore, an intact Ca^2+^ site 2 provides an essential framework for L-Trp recognition. Indeed, introducing a hydrophobic residue at this site through mutations T100I, N102I, or T145I nearly eliminated Ca^2+^-induced receptor activity ([Figure 4D](#fig4){ref-type="fig"}; [Figure 6A,B](#fig6){ref-type="fig"}).

Site 3 is positioned at the edge of the interdomain cleft in LB2 domain ([Figure 5A,B](#fig5){ref-type="fig"}). The Ca^2+^ ion is coordinated by the hydroxyl groups of S302 and S303 either directly (site 3′) or indirectly through water molecules. Alignment of the inactive and active structures in this region showed a small conformational change ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Ca^2+^ ion stabilizes a loop conformation that permits an interdomain hydrogen bond between the neighboring LB2 residue S301 and LB1 residue R66. Such interaction enhances domain closure of CaSR ECD for receptor activation.

Among all four Ca^2+^-binding sites in CaSR ECD structure, site 4 is most closely associated with receptor activation because it directly participates in the formation of an active receptor conformation. Site 4 is part of the homodimer interface formed upon agonist binding, bridging the LB2 domain of one subunit and CR domain of the second subunit ([Figure 5A,B](#fig5){ref-type="fig"}). The Ca^2+^ ion is coordinated by three interfacial residues, including the carboxylate group of D234 and carbonyl oxygen of E231 and G557 ([Figure 5B](#fig5){ref-type="fig"}). The natural mutation G557E ([@bib24]) reduced the potency of Ca^2+^ possibly by affecting backbone conformation, thereby weakening the affinity of Ca^2+^ for this site ([Figure 6A,B](#fig6){ref-type="fig"}). Our structural data indicate that the Ca^2+^ ion at site 4 stabilizes the active conformation of the receptor by facilitating homodimer interactions between the membrane-proximal LB2 and CR domains.

The Ca^2+^ ions have different peak heights in the anomalous difference maps, which are correlated with different Ca^2+^-occupancies at various sites. The Ca^2+^ ions at sites 1 and 2 have strong peaks (12.1--13.1 σ), indicating that these are high-occupancy sites. The Ca^2+^ ions at sites 3 (7.3 -- 9.0 σ) and 4 (5.8 σ) have weaker anomalous peaks, which suggest low occupancy and possibly low affinity. The Ca^2+^ ion at site 4 has the weakest peak compared with other sites, which is consistent with the site being occupied only at elevated Ca^2+^ concentration for receptor activation.

Anion binding {#s2-6}
-------------

We identified a total of four anion-binding sites in the inactive and active CaSR ECD structures based on anomalous difference maps (1--4 or 1\'-4' in the second protomer) ([Figure 7](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}; [Table 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Sites 1--3 are located above the interdomain cleft in the LB1 domain, and site 4 is part of LB2 domain.10.7554/eLife.13662.019Figure 7.Anion-binding sites.(**A**) Inactive-state structure showing peaks in anomalous difference Fourier map (green mesh; 3σ) that correspond to bound SO~4~^2-^ ions. Sites are labeled 1--3 or 1\'-3\' for each protomer. (**B**) Specific contacts between CaSR ECD and each bound SO~4~^2-^ ion within one protomer of the inactive structure. Anomalous difference Fourier map (green): 3.5σ. Fo-Fc map (blue): 4σ. Dashed lines represent hydrogen bonds. (**C**) Active-state structure showing peaks in anomalous difference Fourier map (green mesh; 3σ) that correspond to bound PO~4~^3-^ ions. Sites are labeled 2 and 4 or 2\' and 4\' for each protomer. (**D**) Specific contacts between CaSR ECD and each bound PO~4~^3-^ ion within one protomer of the active structure. Anomalous difference Fourier map (green): 3.5σ. Fo-Fc map (blue): 4σ. (**E**) Active-state structure of CaSR ECD showing the additional hydrogen bonds formed across the interdomain cleft in the absence of any bound anion at sites 1 and 3 (left). Comparison of inactive (red) and active (light blue) structures in the region of anion binding sites 1 (center) and 3 (right).**DOI:** [http://dx.doi.org/10.7554/eLife.13662.019](10.7554/eLife.13662.019)10.7554/eLife.13662.020Figure 7---figure supplement 1.Anion-binding sites in the active homodimer.(**A**) Active-state structure of CaSR ECD showing the peaks in anomalous difference Fourier map (3σ) that correspond to bound PO~4~^3-^ ions. The sites are labeled 2 and 4 or 2\' and 4\' for each protomer. (**B**, **C**) Specific contacts between CaSR ECD and each bound PO~4~^3-^ ion within both protomers of the active structure. Anomalous difference Fourier map (green): 3.5σ. Fo-Fc map (blue): 4σ. Dashed lines represent hydrogen bonds.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.020](10.7554/eLife.13662.020)

In the inactive structure, electron densities revealed that anions were bound at sites 1--3 ([Figure 7A,B](#fig7){ref-type="fig"}). In the active structure, only sites 2 and 4 are occupied ([Figure 7C,D](#fig7){ref-type="fig"}). We modeled the anions as SO~4~^2-^ ions in the inactive state and PO~4~^3-^ ions in the active state given their respective presence in the crystallization reagents. It is also possible that endogenous anions other than SO~4~^2-^ and PO~4~^3-^ are bound at these sites.

The anion at site 1 is coordinated by the guanidine group of R62 and backbone nitrogen of Y63 ([Figure 7B](#fig7){ref-type="fig"}). In the absence of a bound anion in the active state, the side chain of LB1 residue R62 reaches across the interdomain cleft to form a salt bridge with E277 of LB2 domain ([Figure 7E](#fig7){ref-type="fig"}). This contact stabilizes the closed conformation of the CaSR VFT module.

The anion bound at site 2 is held in place by multiple hydrogen bonds with the side chains of R66, R69, W70, and S417, and main chains of R415, I416, and S417 ([Figure 7B,D](#fig7){ref-type="fig"}). The structural integrity of this site is important for receptor function. Each of the mutations R66H, R69E, and S417L essentially eradicated receptor signaling ([Figure 8A,B](#fig8){ref-type="fig"}). Among these, R66H is a disease-associated mutation ([@bib24]; [@bib47]).10.7554/eLife.13662.021Figure 8.Mutational analysis of anion-binding sites.(**A**, **B**) Dose-dependent Ca^2+^-stimulated IP accumulation (**A**) and intracellular Ca^2+^ mobilization (**B**) in cells transiently expressing wt or mutant CaSR. Naturally-occurring inactivating mutations R66H, R69E, and S417L are located at anion-binding site 2 (or 2\'). (**C**) Effect of SO~4~^2-^ ion on Ca^2+^-stimulated IP accumulation in cells transiently expressing wild-type CaSR.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.021](10.7554/eLife.13662.021)

Anion-binding site 3 is adjacent to site 2. The bound anion is also coordinated by R66 and additionally by T412 ([Figure 7B](#fig7){ref-type="fig"}). In the active state, the side chain of LB1 residue R66 forms a hydrogen bond with S301 of LB2 domain ([Figure 7E](#fig7){ref-type="fig"}). This interaction also serves to maintain the CaSR ECD in a closed conformation.

The anion at site 4 is coordinated by H192, T195, K225 and R520 in the active structure ([Figure 7D](#fig7){ref-type="fig"}). In the absence of a bound anion, the side chains of several binding-site residues are disordered in the inactive structure. This indicates that the anion serves to stabilize the local conformation of the receptor structure.

We measured the effect of anion on Ca^2+^-dependent receptor response and found that the presence of SO~4~^2-^ slightly decreased receptor activity, increasing the EC~50~ of Ca^2+^ by approximately 25% ([Figure 8C](#fig8){ref-type="fig"}). This finding confirmed that anions have a negative allosteric effect on the receptor.

Discussion {#s3}
==========

Implications for agonist-dependent receptor activation {#s3-1}
------------------------------------------------------

Our structural analyses of CaSR ECD provide direct evidence that amino acids are agonists of CaSR, and they act concertedly with Ca^2+^ to achieve full receptor activation. L-Trp, the amino acid used in this study, fits the role of an orthosteric agonist for CaSR. (1) It binds at the interdomain crevice of the VFT module, the canonical agonist-binding site for class C GPCRs ([@bib18]; [@bib34]; [@bib42]; [@bib67]). (2) L-Trp shares a common receptor-binding mode with the endogenous agonists of mGluRs and GABA~B~ receptor, which are also amino acids or their analogs ([@bib18]; [@bib34]; [@bib42]; [@bib67]). The residues involved in agonist recognition are located at the same positions in the structures of these receptors ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). For example, a conserved serine residue is responsible for securing the carboxylate of L-Trp, glutamate and GABA in CaSR (S147), mGluRs (S165) ([@bib34]) and GABA~B~ receptor (S130) ([@bib18]), respectively. (3) L-Trp interacts with both LB1 and LB2 domains to facilitate extracellular domain closure, a crucial first step during CaSR activation. In contrast, no Ca^2+^ ion is found at the putative orthosteric agonist-binding site to induce domain closure. (4) Mutations of L-Trp-binding residues completely blocked Ca^2+^-induced IP accumulation and intracellular Ca^2+^ mobilization ([@bib63]; [@bib79]), indicating that L-Trp is required for Ca^2+^-mediated receptor response. (6) L-Trp directly activates CaSR-mediated intracellular Ca^2+^ mobilization in the presence of extracellular Ca^2+^.

On the other hand, Ca^2+^ ion fulfills at least three functional roles. First, it maintains the structural integrity of CaSR, as manifested by the importance of Ca^2+^-binding site 2 for receptor function. Second, it is directly involved in receptor activation. Specifically, the Ca^2+^ ion at site 4 stabilizes the unique homodimer interface between membrane-proximal LB2 and CR domains in the active state. Third, Ca^2+^ enhances L-Trp binding to CaSR ECD, possibly by reinforcing the L-Trp bound and active conformation of the receptor. Furthermore, the actions of Ca^2+^ and amino acids on CaSR are inter-dependent. While the presence of extracellular Ca^2+^ above a threshold level is required for amino-acid-mediated CaSR activation, amino acids increase the sensitivity of the receptor toward Ca^2+^. Taken together, we conclude that amino acids and Ca^2+^ ions are indeed co-agonists of CaSR, acting jointly to trigger receptor activation.

This then led us to an intriguing question: How does Ca^2+^ ion activate the receptor on its own as demonstrated in various cell-based functional assays? It is possible that amino acids are present in cell culture media and extracellular fluid at sufficient concentration to prime the receptor to respond to increasing concentrations of Ca^2+^. We have obtained crystals of CaSR ECD in the absence of any additional amino acids. Nevertheless, the structure showed a stretch of continuous density in the interdomain cleft that may belong to an endogenous ligand ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [Table 1---source data 2](#SD2-data){ref-type="supplementary-material"}). Despite multiple attempts, we have not been able to identify the structure of this endogenous ligand through mass spectrometry. In light of the L-Trp-bound CaSR ECD structure, we reason that the endogenous ligand may be an amino acid or even a mixture of amino acids. In the inactive structure, the endogenous ligand was likely removed by citrate buffer (pH 5.5) during enzymatic deglycosylation.

Metabolic balances of Ca^2+^ and PO~4~^3-^ are linked through hormonal factors such as parathyroid hormone and fibroblast growth factor-23, which control the homeostasis of both ions ([@bib8]; [@bib52]; [@bib68]). We therefore reason that the physiologically relevant anion bound to CaSR is likely PO~4~^3-^, which primarily exists in a HPO~4~^2-^/H~2~PO~4~^-^ mixture in biological systems. First, the anion at site 2 is required for structural stability of the receptor. Second, the anions at sites 1 and 3 appear to stabilize the inactive conformation. Binding of anions at these sites prevent favorable interactions across the interdomain cleft that promote VFT closure. Third, the presence of anion decreases CaSR-mediated IP accumulation. Therefore, these anions may exert a negative modulatory effect on CaSR activity.

The presence of anion-binding sites in CaSR may also provide a mechanism for CaSR to sense polycations such as polyamines. Increasing concentrations of polyamines could potentially compete with arginine residues at the anion-binding sites to bind to PO~4~^3-^, thereby prompting the dissociation of PO~4~^3-^ from relatively weak sites, and releasing their inhibitory effect on the receptor. This would drive CaSR toward its active-state conformation. Our hypothesis would predict that polycations with higher number of positive charges will be more effective agonists. Indeed, previous studies have shown that polyamines mediate an increase in intracellular inositol phosphate and Ca^2+^ accumulation with the rank order seprmine \> spermidine \> putrescine ([@bib10]; [@bib53]).

In summary, activation of CaSR involves an intricate interplay of amino acids, Ca^2+^, and possibly PO~4~^3-^ ions. Like other GPCRs ([@bib59]), CaSR exists in a conformational equilibrium between inactive and active states ([Figure 9](#fig9){ref-type="fig"}). (1) CaSR adopts an open conformation in the resting state, and PO~4~^3-^ ions promote the inactive configuration. (2) An L-amino acid closes the groove in the extracellular VFT module, thereby inducing the formation of a novel homodimer interface between subunits. (3) Ca^2+^ ions stabilize the active state by enhancing homodimer interactions between membrane-proximal domains to fully activate the receptor. The combination of agonist-induced VFT closure and specific association of membrane-proximal CR domains in CaSR will likely lead to rearrangement of the transmembrane domains for receptor activation.10.7554/eLife.13662.022Figure 9.Activation mechanism of CaSR.The schematic diagram shows the equilibrium between the resting and active states of CaSR and the effects of L-amino acid and Ca^2+^ binding.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.022](10.7554/eLife.13662.022)

Common class C GPCR activation mechanism {#s3-2}
----------------------------------------

Structural and functional data suggest a universal activation mechanism for class C GPCRs. First, agonist causes VFT closure in all three receptor systems of CaSR, mGluRs and GABA~B~ receptor. Second, receptor activation requires the association of membrane-proximal domains. For CaSR, this involves the formation of a novel homodimer interface between the LB2 and CR domains. For GABA~B~ receptor, which lacks the CR region, agonist leads to the formation of a large heterodimer interface between the LB2 domains ([@bib18]). Similarly for mGluRs, single-molecule fluorescence resonance energy transfer (FRET) studies indicate that the LB2 domains of mGluRs come into proximity to stabilize the active state ([@bib69]). Furthermore, disulfide crosslinking experiments of mGluR demonstrate that a precise association between the CR domains is sufficient for full receptor activation ([@bib27]). Third, agonist binding is accompanied by a decrease in separation between the C-terminal ends of extracellular domains. This will likely result in rearrangement of the transmembrane domain dimer for receptor activation. Indeed, FRET and crosslinking studies have detected movement between interacting transmembrane domains of mGluRs and GABA~B~ receptor upon activation ([@bib37]; [@bib65]; [@bib76]). In conclusion, agonist-induced VFT closure that leads to the specific association of membrane-proximal domains is a common mechanism shared by all class C GPCRs during ligand-dependent receptor activation.

Materials and methods {#s4}
=====================

Protein expression and purification {#s4-1}
-----------------------------------

The extracellular domain of human CaSR (1--612) was cloned into the pFBDM vector ([@bib4]) for expression in baculovirus-infected insect cells. Wild-type CaSR was heavily glycosylated, and we took two approaches to remove carbohydrates from CaSR ECD: (1) elimination of potential glycosylation sites through mutation, and (2) enzymatic deglycosylation.

Mutants of CaSR ECD were generated in which either two or three N-linked glycosylation sites were eliminated. Both mutant constructs contained the mutations N386Q and S402N, while one also had the additional mutation N468Q. A Flag tag was engineered at the C-terminus of each construct to facilitate affinity purification. In agreement with previous studies of full-length CaSR in mammalian cells ([@bib54]), we found that expression of CaSR ECD in insect cells was essentially eliminated when more than three glycosylation sites were disrupted. The CaSR ECD glycosylation mutants were constructed to maximize the reduction of carbohydrate content while maintaining a sufficient expression level for structural studies.

Wild-type and mutant CaSR ECD were secreted from sf9 insect cells infected with the corresponding recombinant CaSR ECD virus. The CaSR ECD protein was isolated from cell supernatant by anti-Flag antibody (M2) affinity chromatography, and eluted with 100 µg/ml Flag peptide in 50 mM Tris, pH 7.5 and 150 mM NaCl. The protein was further purified by gel filtration chromatography (superdex 200, GE Healthcare Life Sciences, USA) in 20 mM Tris, pH 8.0 and 150 mM NaCl to remove aggregates. Finally, the CaSR ECD protein was applied to an ion exchange column (MonoQ, GE) in 20 mM Tris, pH 8.0 and eluted using a linear salt gradient from 0 to 1 M NaCl. All purification procedures were performed in the presence of 10 mM CaCl~2~. To isolate the L-Trp-bound receptor, purified CaSR ECD protein was washed extensively with a solution containing 20 mM Tris, pH 8.0, 10 mM L-Trp, and 10 mM CaCl~2~ prior to crystallization. This would facilitate the complete saturation of L-Trp- and Ca^2+^-binding sites within the receptor.

We applied an enzymatic deglycosylation procedure to wild-type receptor and the CaSR ECD mutant with two glycosylation-site mutations. Each construct was expressed in sf9 cells in the presence of the N-glycosylation processing inhibitor kifunensine (1 mg/L) to produce high mannose glycoproteins that were sensitive to enzymatic cleavage by endoglycosidase H (Endo H). The cell supernatant was applied to an M2 anti-Flag antibody affinity column, and the bound CaSR ECD protein was eluted with 100 µg/ml Flag peptide in 50 mM Tris, pH 7.5 and 150 mM NaCl. Well-folded CaSR ECD was separated from aggregates by gel filtration chromatography in 20 mM Tris, pH 8.0, and 150 mM NaCl. The CaSR ECD protein was subsequently digested overnight with Endo H in 50 mM Na Citrate, pH 5.5. The partially deglycosylated CaSR ECD protein was further purified by ion exchange chromatography in 20 mM Tris, pH8.0 using a linear salt gradient from 0 to 1 M NaCl. The protein purification and enzymatic deglycosylation procedures were performed either in the absence or presence of 2 mM CaCl~2~, which is within the normal range of Ca^2+^ concentrations in plasma.

Crystallization and data collection {#s4-2}
-----------------------------------

Wild-type CaSR ECD did not form well-diffracting crystals possibly because the presence of flexible and heterogeneous carbohydrates on the protein surface interfered with crystallization.

The CaSR ECD mutant carrying two glycosylation-site mutations formed diffracting crystals after enzymatic deglycosylation. The crystals were obtained at 20°C in 1.5 M Li~2~SO~4~, 100 mM Tris pH 8.5 in the absence and presence of 2 mM CaCl~2~. Protein crystallization was achieved by hanging drop vapor diffusion method using 24-well VDX plates (Hampton Research, USA). The CaSR ECD crystals were flash-cooled with liquid nitrogen in a cryoprotecting solution containing 3.0 M Li~2~SO~4~, 100 mM Tris pH 8.5, and the same concentration of CaCl~2~ as used for crystallization. These CaSR ECD crystals have the space group F222 with one molecule per asymmetric unit (form I).

The CaSR ECD mutant carrying three glycosylation-site mutations crystallized under two different conditions. (1) In the absence of additional amino acids, CaSR ECD formed the best diffracting crystals at 20°C in 0.9 M Na Citrate, 100 mM Tris, pH 8.0, and 10 mM CaCl~2~. The crystals were obtained using hanging drop vapor diffusion technique. These crystals were flash-cooled with liquid nitrogen in a cryoprotecting solution containing 0.9 M Na Citrate, 100 mM Tris, pH 8.0, 10 mM CaCl~2~, and 20% glycerol. (2) Crystals of the L-Trp-bound CaSR ECD mutant were grown at 20°C in 1.6 M NaH~2~PO~4~, 0.4 M K~2~HPO~4~, 100 mM Na~2~HPO~4~/citric acid pH 4.2, 10 mM CaCl~2~, and 10 mM L-Trp. The crystals were obtained by sitting drop vapor diffusion method using 24-well Cryschem plates (Hampton Research). These crystals were flashed-cooled with liquid nitrogen in a cryoprotecting solution containing 20% glycerol and all other components of the crystallization solution. The crystals obtained from both conditions belong to space group C2 and have two molecules per asymmetric unit (form II).

Diffraction data were collected at the 24ID-C and 24ID-E beamlines of Advanced Photon Source (APS). To minimize radiation damage at low energy, a native dataset was collected at the energy of Se-K edge (λ=0.9792 Å) for a single form I crystal of CaSR ECD grown in the presence of 2 mM Ca^2+^. This native dataset was used to solve the inactive-state CaSR ECD structure. Form I crystals grown in the absence of additional Ca^2+^ diffracted to much lower resolution than those obtained in the presence of 2 mM Ca^2+^ and were therefore not used for structural determination.

Multiple anomalous data sets were also collected at λ = 1.7712 Å for form I crystals of CaSR ECD, each from a single crystal. A total of five anomalous data sets were obtained for CaSR ECD in the absence of Ca^2+^. These data sets were integrated individually by XDS ([@bib30]), and then scaled and merged using CCP4 programs ([@bib73]) to calculate the anomalous difference Fourier maps in the absence of additional Ca^2+^. Similarly, eight anomalous data sets were collected for CaSR ECD in the presence of 2 mM Ca^2+^, and combined to determine the anomalous difference Fourier maps in the presence of plasma concentration of Ca^2+^. The anomalous difference maps obtained in the absence and presence of Ca^2+^ revealed peaks that correspond to bound Ca^2+^ and SO~4~^2-^ ions at the same positions in the CaSR ECD structure. The averaging of multiple data sets enhanced signal to noise in anomalous diffraction ([@bib35]).

A total of four anomalous data sets were collected at low energy (λ=1.7712 Å) for L-Trp-bound form II crystals of CaSR ECD, each from a single crystal. The four data sets were processed individually by XDS ([@bib30]) and CCP4 programs ([@bib73]). The data set with the highest resolution limit (2.6 Å) was used to determine the active-state CaSR ECD structure in the presence of L-Trp and excess Ca^2+^. The four data sets were also scaled and merged for the calculation of anomalous difference Fourier maps.

Structure determination {#s4-3}
-----------------------

The structure of L-Trp-bound CaSR ECD in form II crystal was solved by molecular replacement. A two-fold non-crystallographic symmetry (NCS) axis was identified from the self-rotation function. Polyalanine models generated from the individual LB1 and LB2 domains of mGluR3 ECD structure ([@bib42]) (PDB code: 2E4U) were used as search probes to locate the VFT modules of both CaSR ECD molecules in the crystal. After phase improvement by two-fold NCS-averaging, additional density appeared for the CR domain of CaSR ECD. A complete model of the CaSR ECD homodimer was developed through a succession of manual fittings and iterative refinement. The final model contained the CaSR ECD residues 20--119, 135--359 and 393--598 in one protomer, and residues 22--122, 136--360 and 392--602 in the other protomer. Each protomer contained eight intrasubunit disulfide bridges. Electron density was visible for carbohydrate residues (N-acetyl-glucosamine) attached to Asn90, Asn287, Asn488, Asn541 of one protomer, and Asn541 of its dimer partner. Finally, each protomer was also bound to one L-Trp ligand, four Ca^2+^ ions, and two PO~4~^3-^ ions. The Ca^2+^ and PO~4~^3-^ ions were identified by anomalous difference Fourier maps calculated using data collected at a wavelength of 1.7712 Å. We modeled PO~4~^3-^ as the anions in the CaSR ECD structure because they were major components of the crystallization solution. The anomalous scattering of Ca^2+^ at 1.75 Å has been used successfully to identify the Ca^2+^-binding sites in a voltage-gated calcium channel ([@bib64]). Ramachandran analysis places 94.9% of all residues in favored regions and 0.28% in outlier regions.

A molecular replacement solution was also obtained for CaSR ECD in form II crystal in the presence of 10 mM Ca^2+^ but absence of any additional amino acid. The protein structure of L-Trp-bound CaSR ECD without any bound ligand was used as the search model. A stretch of electron density at the interdomain cleft region indicates the presence of an endogenous ligand. This structure was partially refined because we have not been able to identify the structure of the endogenous ligand by mass spectrometry despite multiple attempts.

The structure of partially deglycosylated CaSR ECD in form I crystal was solved using the individual LB1, LB2, and CR domains of L-Trp-bound CaSR ECD as search models. The asymmetric unit of the form II crystals contained one CaSR ECD protomer, and it forms a disulfide-linked homodimer with a crystallographic symmetry-related molecule. The final model for a single protomer contained CaSR ECD residues 21--130 and 136--603. In addition to the eight intrasubunit disulfide linkages within each protomer, the inter-subunit disulfide bond formed by C129 was ordered in the form I CaSR ECD crystal structure. Electron density was also visible for carbohydrate residues (N-acetyl-glucosamine) attached to Asn261, Asn287, Asn446, Asn468, Asn488, Asn541, and Asn594. In addition, each protomer had one Ca^2+^ ion, and three SO~4~^2-^ ions. The Ca^2+^ and SO~4~^2-^ ions were identified by anomalous difference Fourier maps calculated from data collected at 1.7712 Å. We reasoned that SO~4~^2-^ ions were most likely the anions bound to CaSR ECD since they were used as the precipitant for crystallization. Geometric analysis places 92.9% of all residues in favored regions and 0.35% as outliers. In the form I CaSR ECD structure, the interdomain groove was empty except for a water molecule; it also forms crystal contacts with a symmetry-related molecule.

Molecular replacement searches were carried out using PHASER ([@bib38]). Model building was performed with COOT ([@bib17]). Structural refinement was executed using BUSTER ([@bib60]). Anomalous difference Fourier maps were calculated with PHENIX ([@bib1]). Ramachandran statistics were obtained for each structure using MolProbity ([@bib9]). Pairwise structural comparison was performed using LSQMAN ([@bib46]). Protein contacts were analyzed using the CCP4 program CONTACT ([@bib11]). Software installation support was provided by SBGrid ([@bib39]).

Cell surface expression {#s4-4}
-----------------------

Full-length human CaSR was cloned into a pcDNA3.1(+) vector (Life Technologies, USA) for expression in human embryonic kidney (HEK) 293 cells. A Flag tag was inserted after the signal peptide of CaSR. Mutants of CaSR were constructed using the QuikChange mutagenesis system (Agilent Technologies, California, USA).

HEK293 T/17 cells (ATCC) were transfected by Lipofectamine 2000 (Life Technologies) with wild-type or mutant CaSR plasmids. Cells permeabilized with 0.5% Triton X100 were used to determine the total expression level of CaSR in transfected cells. Untreated cells were used to determine the cell surface expression level of the receptor. The amount of surface protein detected for each construct was normalized to that found in the total cell lysate.

The cells were blocked with 5% milk, and then incubated with mouse anti-Flag M1 antibody (Sigma-Aldrich, USA) as the primary antibody to measure CaSR expression. Donkey anti-mouse IRDye 800-labeled antibody (LiCor Biosciences, Nebraska, USA) was used as the secondary antibody. Fluorescent signals were measured with an Odyssey Infrared Imager (LiCor). The results of three independent experiments were used for statistical analysis.

Most of the mutants were expressed on the cell surface at levels comparable to that of the wild-type receptor. The exceptions were R66H, R69E, I81M, T100I, N102I, and S417L, which reduced the surface expression of the mutant receptors to approximately 70--75% of the wild-type level.

Inositol phosphate measurement {#s4-5}
------------------------------

Measurement of inositol phosphate (IP) accumulation was carried out using the homogenous time-resolved fluorescence (HTRF) IP-one Tb kit (Cisbio Bioassays, USA). This assay quantifies the accumulation of inositol 1-monophosphate (IP~1~), a degradation product of inositol 1,4,5-triphosphate (IP~3~) that is stable in the presence of LiCl. Briefly, HEK293 T/17 cells were transiently transfected with wild-type or mutant full-length CaSR plasmids. The cells were stimulated with increasing concentrations of Ca^2+^ two days post transfection in a buffer containing 10 mM HEPES pH 7.4, 0.5 mM MgCl~2~, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, and 50 mM LiCl. The reaction mixture was then incubated with an IP1 analog coupled to a d2 fluorophore (acceptor) and an anti-IP1 monoclonal antibody labeled with Eu Cryptate (donor). The IP1 produced by cells upon activation of CaSR competes with IP1 coupled to the dye d2 for binding to the anti-IP1 antibody. The resulting FRET signal is inversely proportional to the concentration of IP1 in the sample. The fluorescence data was acquired at 620 and 665 nm using an EnVision plate reader (Perkin Elmer, USA) after laser excitation at 320 nm. The FRET signal was calculated as the fluorescence ratio (665 nm/620 nm). Basal activity was determined in the absence of Ca^2+^ stimulation. The percent stimulation of each receptor mutant was calculated based on the wild-type response obtained under the same condition. Data analysis was performed using the non-linear regression algorithms in Prism (GraphPad Software, USA). Data points represent average ± s.e.m. of triplicate measurements.

The effect of anion on Ca^2+^-stimulated IP accumulation was determined using SO~4~^2-^ instead of PO~4~^3-^ because of the modest solubility of CaHPO~4~ (1.5 mM), the predominant form of calcium phosphate salt at physiological pH (7.4). Specifically, dose-dependent Ca^2+^-induced IP accumulation was measured in the absence and presence of 10 mM Li~2~SO~4~ in the reaction buffer.

Intracellular Ca^2+^ flux measurement {#s4-6}
-------------------------------------

Measurement of intracellular Ca^2+^ mobilization was performed using a FLIPR Fluorescent Imaging Plate Reader (FLIPR) Calcium Assay kit (Molecular Devices). Briefly, HEK293 cells were transiently transfected with wild-type or mutant full-length CaSR plasmids and cultured overnight. The cells were incubated in a loading medium containing 50% Opti-MEM, 50% Ca^2+^-free Hank's balanced salt solution, 2.5% fetal bovine serum, 20 mM HEPES pH 7.4, 2.5 mM probenecid and 2 µM fluorescent Ca^2+^ indicator Fluo-4 AM (Life Technologies) for 1 hr, and then placed into the FLIPR. CaCl~2~ (prepared in Hank's balanced salt solution and 20 mM HEPES, pH 7.4) was added at 10 s, and changes in fluorescence were monitored over a period of 250 s following excitation at a wavelength of 488 nm and detection at 510--560 nm. Data analysis was performed using the non-linear regression algorithms in Prism (GraphPad Software). Data points represent average ± s.e.m. of triplicate measurements.

To measure the potentiating effect of L-Trp on the response of CaSR to extracellular Ca^2+^, HEK293 cells were transiently transfected with wild-type CaSR plasmid and cultured for 48 hr. The cells were washed three times with an assay buffer (20 mM HEPES, pH 7.4, 1 mM CaCl~2~, 1 mM MgCl~2~, 1 mg/ml BSA, 5.5 mM D-glucose, 5.3 mM KCl, 138 mM NaCl, 4.2 mM NaHCO~3,~ 0.44 mM KH~2~PO~4~, 0.34 mM Na~2~HPO~4~) to remove any endogenously bound ligand, and pre-incubated with 10 mM L-Trp for 20 min before stimulation with extracellular Ca^2+^.

Single-cell intracellular Ca^2+^ microfluorimetry {#s4-7}
-------------------------------------------------

HEK293 cells that stably expressed the CaSR (HEK-CaSR cells) were cultured on coverslips in 24-well plates, and loaded in the dark with fura2-AM (5 µM) in physiological saline solution (PSS; 125 mM NaCl, 4 mM KCl, 0.1% w/v D-glucose, 1 mM MgCl~2~, 20 mM HEPES-NaOH, pH 7.45) that contained 1 mM CaCl~2~, 0.8 mM NaH~2~PO~4~ and 1 mg/ml BSA for 1.5 hr at 37°C. The cells were washed and stored in a fura2-AM-free loading solution prior to experiments. Fura2-loaded HEK-CaSR cells were transferred into a perifusion chamber, placed in the light path of a Zeiss Axiovert fluorescence microscope (Zeiss, USA), and perifused with PSS containing various concentrations of Ca^2+^ and L-Trp.

Fura2-loaded HEK-CaSR cells were excited by a Lambda DG-4 150 Watt xenon light source (Sutter, Novato, USA), using alternating wavelengths of 340 and 380 nm at 0.5 s intervals, and imaged at 510 nm. For each data set, regions of interest corresponding to the locations of 10 individual cells were selected and digital images were captured using an AxioCam camera controlled by Stallion SB.4.1.0 PC software (Intelligent Imaging Innovations, USA).

Single-cell intracellular Ca^2+^ mobilization data consisted of excitation ratios (F340/F380) plotted against time (min). Ratio data were integrated, expressed as integrated response units (IRUs), and corrected for baseline (PSS containing 0.5 mM Ca^2+^). Concentration-dependent response data were fitted to the equation:$$R = b + \left( a - b \right)\, C^{n}/\left( e^{n} + C^{n} \right)$$

in which: *a* = maximum response; *b* = basal response; *C* = activator concentration; *e* = EC~50~ in mM; and *n* = Hill co-efficient. Estimates of curve-fitting parameters were obtained using Prism (GraphPad Software).

Scintillation proximity assay {#s4-8}
-----------------------------

Wild-type CaSR ECD protein was purified by anti-Flag M2 antibody affinity chromatography and gel filtration chromatography in the absence of additional CaCl~2~ and amino acids. The protein was incubated in 100 mM NaCitrate, pH 5.5 overnight to remove any endogenously bound ligand. The CaSR ECD protein was then separated from any free ligand by gel filtration chromatography in 20 mM HEPES, pH 8.0 and 150 mM NaCl.

Binding of 0.1 mM L-\[^3^H\]Trp (1 Ci/mmol) to 600 ng of purified CaSR ECD was measured with the scintillation proximity assay (SPA) using 1.25 mg/mL Yttrium silicate (YSi) protein A SPA beads (PerkinElmer, USA) in conjunction with 0.125 ng/mL of anti-Flag M2 antibody in 20 mM HEPES, pH 8.0 and 150 mM NaCl at 4°C. Increasing concentrations of non-radioactive L-Trp were added to compete for receptor binding in the presence of 0 mM or 2 mM CaCl~2~. Each reaction was also performed in the presence of 60 mM non-radioactive L-Trp for background correction. The reactions were allowed to proceed for 1 hr to reach equilibrium. The plates were then counted in a Microbeta counter (PerkinElmer, USA). Data were analyzed using the non-linear regression algorithms in Prism (GraphPad).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Structural mechanism of ligand activation in human calcium-sensing receptor\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Ehud Isacoff as a guest Reviewing Editor and Randy Schekman as the Senior Editor. One of the three reviewers has agreed to reveal their identity: Yoshihiro Kubo.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Geng et al. describe the first crystal structures of the calcium-sensing receptor (CaSR), a G protein-coupled receptor (GPCR). These structures of the extracellular domain demonstrate that L-Trp is an orthosteric agonist of the receptor and reveal binding sites for modulating Ca^2+^ and PO~4~^3-^ ions. Structures in four pharmacologically relevant conditions reveal two distinct conformations consistent with a model of an activation rearrangement that is triggered by venus flytrap closure on agonist, which positions the cysteine-rich domains of the subunits in close proximity -- consistent with earlier structural and biochemical analysis on other class C GPCRs. The study suggests that positive and negative allosteric modulation by Ca^2+^ and PO~4~^3-^ ions act occurs via modulation of the binding of the orthosteric agonist.

Essential revisions:

1\) Evaluate the L-Trp EC~50~ in cell-based assays using different ionic conditions (such as no Ca^2+^ to 10 mM Ca^2+^).

2\) To demonstrate the inhibitory effect of PO~4~^3-^ on the response of CaSR to Ca^2+^, compare responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of PO~4~^3-^, in wt and mutants of the anion binding sites.

3\) To demonstrate the potentiating effect of L-Trp on the response to Ca^2+^, compare responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of L-Trp, in wt and mutants of the L-tryptophan binding sites.

Reviewer \#1:

The manuscript by Geng et al. describes the crystal structures of the human calcium-sensing G protein-coupled receptor extracellular domain (ECD). In a nutshell, these structures demonstrate that L-Trp is an orthosteric agonist of the receptor and reveal several binding sites for Ca^2+^ and PO~4~^3-^ ions that, based on mutagenesis data and functional assays, may play a key role in balancing receptor activity.

In particular, the structures were obtained in four different pharmacologically relevant conditions (with or without Ca^2+^ and L-Trp) and revealed only two distinct conformations. Based on the structural information available for the same receptor family (class C GPCRs), the authors propose that these two conformations represent inactive and active states of the receptor. They provide a detailed comparison of both structures to highlight the rearrangement of the ECDs that is necessary for receptor activation. Of note, this is the first structure in the class C family in which the cystein rich domain (CRD) adopt such a conformation in an agonist bound condition. This structure nicely fits the crosslinking data obtained for the metabotropic glutamate receptors in living cells and thus validate the ECD activation model of class C GPCR possessing a CRD domain: an interdomain movement triggered by VFT closure which positions the CRDs in close proximity.

I thus believe this study is of immediate interest to many people in the GPCR field and beyond. Overall the methodology and data are robust and I did not find any flaws that should prohibit its publication.

To conclude, I think it is tempting to speculate that the Ca^2+^ and PO~4~^3-^ ions act respectively as positive and negative allosteric modulators of the CaSR receptor activity by modulating, at least in part, the binding of the orthosteric agonist L-Trp. One key experiment would thus be to evaluate the L-Trp EC~50~ in cell-based assays using different ionic conditions (such as no Ca^2+^ to 10 mM Ca^2+^).

Although this might strengthen the manuscript, I do not believe these data would be critical for publication.

Reviewer \#2:

This is an important manuscript reporting the first crystal structure of CaSR. The structure showed interesting features in terms of ligand binding sites. The binding site for Ca^2+^, a main agonist, was different from the canonical ligand binding sites identified in other class C GPCRs, such as mGluR and GABABR. It is noteworthy that this canonical site in CaSR was occupied by L-tryptophan, a putative co-agonist. These features concerning about binding sites and the proposed activation mechanism of CaSR is unique, in comparison to other class C GPCRs. Therefore, this paper will contribute to facilitate the understanding of physiological and biophysical properties of CaSR and class C GPCR. The authors also identified the putative binding sites for PO~4~^3-^, and suggested that PO~4~^3-^ is an antagonist of CaSR for the first time.

I highly evaluate the scientific merits and the general impact of the paper. I judge it is worthy for publication, but only after satisfactory revisions. I have four major comments which require attention.

1\) Experiments to demonstrate the inhibitory effect of PO~4~^3-^

The conclusion in the Discussion that \" PO~4~^3-^ ions promote the inactive configuration\" is rather speculative from the two reasons in the following.

A\) There are no direct evidence which shows PO~4~^3-^ promotes the inactivated conformation. The authors showed mutants of the PO~4~^3-^ binding sites have lower IP accumulation in response to extracellular Ca^2+^. I think the data are not sufficient. To demonstrate the inhibitory effect of PO~4~^3-^ on the response of CaSR to extracellular Ca^2+^ conclusively, I would like to request to present data comparing the responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of PO~4~^3-^, in wt and mutants of the anion binding sites. The expected result is lower response to Ca^2+^ in the presence of PO~4~^3-^ than in the absence, not in mutants but in wt.

B\) The authors assume that the electron density represents the presence of PO~4~^3-^ or SO~4~^3-^, because there are no anions in the crystallization solution other than PO~4~^3-^ or SO~4~^3-^. Is there a possibility that carryover endogenous anion(s) other than PO~4~^3-^ is bound to the anion binding site? (similarly to the case of the putative carryover of endogenous amino acid(s) at the L-tryptophan binding site when crystalized in the absence of L-tryptophan).

2\) Experiments to demonstrate the potentiating effect of L-tryptophan

I have similar comments to the case of anion effect. To demonstrate the potentiating effect of L-tryptophan on the response of CaSR to extracellular Ca^2+^ conclusively, please present data comparing the responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of L-tryptophan, in wt and mutants of the L-tryptophan binding sites. The expected result is higher response to Ca^2+^ in the presence of L-tryptophan than in the absence, not in mutants but in wt.

3\) Comparison with the mGluR and GABABR

The authors discussed differences and similarities of the CaSR structure to those of mGluR and GABABR. However, it is hard to follow the explanations in the text, without structure images for comparison.

A\) The authors mentioned the degree of rotational change of two LB1 interface in CaSR with GABAB and mGluR upon activation (subsection "Common protomer-protomer interactions", third paragraph). In [Figure 3---figure supplement 1B, D](#fig3s1){ref-type="fig"}, the authors showed two images of CaSR in the resting and activated states. I would like to request to add similar images in the two states of mGluR and GABABR in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, to clarify the discussion of the rotated angle of LB1 interface.

B\) The authors described an overall similarity of VFT cleft structure of CaSR and mGluR. They also wrote the tryptophan binding site of CaSR corresponds to the glutamate binding site of mGluR (subsection "Structure of CaSR ECD homodimer", second paragraph). To clarify these points, please present a superimposed image of the VFT cleft of CaSR and mGluR, in e.g. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

4\) Gd3+ binding site

In the crystal structure of mGluR1, a binding site for Gd3+ was identified at the dimer interface (Tsuchiya et al., PNAS 2002). I would like to have explanations whether or not a similar structure was identified in CaSR.

Reviewer \#3:

Geng et al. reported the crystal structures of entire extracellular domain of calcium sensing receptor of calcium free form and loaded forms in the presence of calcium and PO43- ions. This work is of importance for providing insights for the activation mechanism via dimer interface between subunits. There are several major concerns that need be addressed:

1\) The crystal structures were determined for CaSR with mutations of either two (N386Q and S402N) or three (N468Q) N-glycosylation sites. However, no study has been carried out on the effects of these mutations on expression and function of CaSR. It is important to provide evidence with experimental data that mutations at these glycosylation sites do not result in alteration of the function and expression.

2\) Since mutations could lead to reduction in cell surface expression due to trafficking, it is encouraged to provide confocal images to ensure that the observed change in intracellular IP activity is not due to reduction of protein expression levels on cell surface.

3\) The identification of Trp binding site is very important for the activation mechanism. It will be very helpful to report Trp binding affinity of the ECD of CaSR.

4\) Extremely high concentrations of three different anion ions were used for crystallization. The role of anion binding is not clear and some of them appear to be non-specific. Among 4 anion-binding sites identified, sites 1-3 are in inactive form crystalized with 3.0 M Li2SO4, 100 mM Tris pH8.5 with mutations N386Q and S402N. Under this condition, SO42- ions are assigned. On the other hand, 1.6 M NaH2PO4, 0.4 M K2HPO4, 100 mM Na2HPO4/citric acid pH4.2, 10 mM Trp 10 mM Ca^2+^ are used for identification of anion sites in the active form of CaSR with three glycosylation mutations. Thus, 2 anion binding sites were modeled to be PO43. What is the binding affinity for these anion ions?

5\) The four calcium binding sites shown in [Figure 5](#fig5){ref-type="fig"} either have incomplete coordination or lack of negatively charged residues. These properties are very different from classical calcium binding sites with at least three ligand oxygen atoms from the protein and with electrostatic interactions. The reported site 3 calcium is directly chelated only by one oxygen from hydroxyl side chin of S302. Site 4 is formed by side chain of D234 and mainchain carbonyl oxygen from E231 and G557. How the function results provided in [Figure 6](#fig6){ref-type="fig"} is a mutation G55E that results in a significantly increase of EC50 for IP accumulation and intracellular calcium response. Why have such big alteration of activity for a replacement of another carbonyl oxygen? Since calcium interaction is largely electrostatic, it would make sense to test the mutational effect D234A. The provided mutational studies of I181 m, T100I, and N102I all have significantly reduced maximal amplitudes in both IP and intracellular calcium activities in addition to increased EC50. These results suggest that the surface expression of the mutated protein variants are largely reduced. Thus, the effect for these residues in calcium binding cannot be unambiguously revealed. It is important to provide the results for the mutational effect of these identified ligand residues on direct calcium binding affinity.

6\) It is worth to pointing out that at pH4.2 sidechain of Asp and Glu are largely protonated with significantly reduced calcium binding capability. In addition, due to poor solubility of calcium phosphate, the molar phosphate concentrations used in the buffer will result in extremely low concentration of soluble free calcium. Thus, the role of calcium binding in activation revealed in the determined structures is likely to be under estimated due to the condition used for crystallization.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Structural mechanism of ligand activation in human calcium-sensing receptor\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Randy Schekman (Senior Editor), a Reviewing Editor, and one reviewer.

The manuscript has been improved but there is a remaining issue that needs to be addressed before acceptance, as outlined below:

1\) In the point by point response to Reviewer \#3, comment \#3, the authors stated the following:

\"The presence of 2 mM Ca^2+^ did not affect the binding affinity of L-Trp, indicating that Ca^2+^ion is not directly involved in L-Trp recognition. This is consistent with our structural observation that no Ca^2+^ ion is found at the L-Trp-binding site. Nevertheless, Ca^2+^ ion increased the amount of L-Trp bound to CaSR ECD at any given concentration, indicating that extracellular Ca^2+^ enhances the L-Trp-binding site occupancy, possibly by stabilizing the L-Trp-bound and active conformation of CaSR.\"

The authors should clarify what they mean by this. If calcium stabilized the Trp-bound state it would presumably be seen as an increase in Trp affinity. An increase in amount of radio-Trp that is bound that does not shift the affinity curve would seem to suggest adding to circulation Trp binding sites (i.e. receptors) that were previously not available (from an unavailable/inactive pool?). Or is there another possible explanation? Or does this raise a caveat about the experiment? This should be addressed in the text.

Reviewer \#1:

I believe the revised version of the manuscript \"Structural mechanism of ligand activation in human calcium-sensing receptor\" is addressing the essential revisions that were raised during the first reviewing process. In particular, the authors have addressed the allosteric effect of Ca^2+^ on L-Trp activity (and vice versa).

10.7554/eLife.13662.032

Author response

*Essential revisions:*

1\) Evaluate the L-Trp EC~50~ in cell-based assays using different ionic conditions (such as no Ca^2+^ to 10 mM Ca^2+^).

Following the referees' suggestion, we have evaluated the L-Trp EC50 at different Ca^2+^ concentrations by monitoring changes in CaSR-mediated intracellular Ca^2+^ response in single cells. In agreement with previous findings, L-Trp can activate CaSR when the extracellular Ca^2+^ concentration is above the threshold level of 0.5 mM. The effect of L-Trp on CaSR was concentration-dependent, with an apparent EC50 of 0.12 ± 0.06 mM when extracellular Ca^2+^ was present at 2.5 mM. The efficacy of L-Trp decreased at lower concentrations of Ca^2+^ that are within the physiological range (L-Trp EC50 = 0.75 ± 0.51 mM at 1.5 mM Ca^2+^), consistent with previous proposal that multiple amino acids need to act in concert to control the function of CaSR. The new data are presented in [Figure 4E and 4F](#fig4){ref-type="fig"}.

2\) To demonstrate the inhibitory effect of PO~4~^3-^ on the response of CaSR to Ca^2+^, compare responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of PO~4~^3-^, in wt and mutants of the anion binding sites.

Following the referees' suggestion, we have measured the response of CaSR to extracellular Ca^2+^ in the absence and presence of the anion SO~42-~. We chose SO~42-~ to substitute for PO~43-~ because CaSO~4~ is more soluble than CaHPO~4~, the predominant form of calcium phosphate salt at physiological pH. At pH 7.4, approximately 61.3% of the phosphate ions exist in the form of HPO~42-~ and 38.7% are in the form of H~2~PO~4~^-^. The solubility of CaHPO~4~ and Ca(H~2~PO~4~)2 are 1.5 mM and 71 mM, respectively. The solubility of CaSO~4~ is 15 mM.

As predicted by the referee, and consistent with our structural observation, we found that the response of CaSR to Ca^2+^ was slightly lower in the presence of than in the absence SO~4~^2-^. This confirms that anions have a negative allosteric effect on the receptor. The new data are presented in [Figure 8C](#fig8){ref-type="fig"}.

We have also examined the effects of SO~4~^2-^ on mutants of the anion binding-sites. Our structures revealed that the anion-binding residues R62 at site 1 and R66 at site 3 form hydrogen bonds across the interdomain cleft in the absence of bound anions to stabilize the closed conformation of the receptor. We found that the effect of SO~4~^2-^ on Ca^2+^-induced activation of the R62M mutant was similar to that of the wild-type receptor, while the presence of SO~4~^2-^ had little effect on the activity of the R66H mutant. However, we cannot conclude which anion-binding sites are involved in mediating the inhibitory effect of anions because these mutations are expected to have both positive and negative effects on the receptor function.

A\) The mutations R62M and R66H are expected to eliminate the inhibitory effect of anions by preventing their binding to the receptor.

B\) These same mutations would also disrupt the formation of hydrogen bonds across the interdomain cleft by R62 and R66, thereby eliminating the interactions that favor receptor activation.

C\) Residue R66 is involved in the binding of anion at both sites 2 and 3. Since anion-binding site 2 appears to be crucial for structural integrity of the receptor, disruption of this site by the R66H mutation would negatively affect receptor function.10.7554/eLife.13662.023Author response image 1.Effect of SO~4~^2-^ on Ca^2+^-stimulated IP accumulation in cells transiently expressing wild-type (WT) or mutant CaSR.The mutations R62M and R66H affect arginine residues at anion-binding sites 1 and 3 that form hydrogen bonds formed across the interdomain cleft in the absence of any bound anion.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.023](10.7554/eLife.13662.023)

3\) To demonstrate the potentiating effect of L-Trp on the response to Ca^2+^, compare responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of L-Trp, in wt and mutants of the L-tryptophan binding sites.

Following the referee's suggestion, we have measured the potentiating effect of L-Trp on the response of wild-type CaSR to extracellular Ca^2+^. During the course of our study, we found that it was very difficult to measure the functional effect of L-Trp through IP accumulation. Instead, we monitored the effect of L-Trp on CaSR-mediated intracellular Ca^2+^ mobilization. As predicted by the referee, Ca^2+^-induced receptor activation is higher in the presence of L-Trp than in the absence. The new data are presented in [Figure 4G](#fig4){ref-type="fig"}.

We have shown using IP accumulation measurements that most alanine mutants of the L-Trp- binding site abolished Ca^2+^-dependent receptor response in the absence of any amino acid. Therefore, these mutants would not be suitable for the study of the L-Trp effect. For the two mutants that displayed partial receptor activity (S147A and Y218S), we found that they did not respond to 10 mM L-Trp in the presence of 2 mM extracellular Ca^2+^.10.7554/eLife.13662.024Author response image 2.Effect of various concentrations of L-Trp (1, 2, 0, 10 mM) on intracellular Ca^2+^ mobilization in the presence of 2 mM extracellular Ca^2+^.(**A**) Wild-type (WT) CaSR. (**B**) S147A mutant. (**C**) Y218A mutant.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.024](10.7554/eLife.13662.024)

Reviewer \#1:

I think it is tempting to speculate that the Ca^2+^ and PO~4~^3-^ ions act respectively as positive and negative allosteric modulators of the CaSR receptor activity by modulating, at least in part, the binding of the orthosteric agonist L-Trp. One key experiment would thus be to evaluate the L-Trp EC~50~ in cell-based assays using different ionic conditions (such as no Ca^2+^ to 10 mM Ca^2+^).

*Although this might strengthen the manuscript, I do not believe these data would be critical for publication.*

Following the referee's suggestion, we have evaluated the L-Trp EC50 at different Ca^2+^ concentrations by monitoring changes in CaSR-mediated intracellular Ca^2+^ response in single cells. In agreement with previous findings, L-Trp can activate CaSR when the extracellular Ca^2+^ concentration is above the threshold level of 0.5 mM. The effect of L-Trp on CaSR was concentration-dependent, with an apparent EC50 of 0.12 ± 0.06 mM when extracellular Ca^2+^ was present at 2.5 mM. The efficacy of L-Trp decreased at lower concentrations of Ca^2+^ that are within the physiological range (L-Trp EC50 = 0.75 ± 0.51 mM at 1.5 mM Ca^2+^), consistent with previous proposal that multiple amino acids need to act in concert to control the function of CaSR. The new data are presented in [Figure 4E and 4F](#fig4){ref-type="fig"}.

Reviewer \#2:

*I highly evaluate the scientific merits and the general impact of the paper. I judge it is worthy for publication, but only after satisfactory revisions. I have four major comments which require attention.*

1\) Experiments to demonstrate the inhibitory effect of PO~4~^3-^

*The conclusion in the Discussion that \" PO~4~^3-^ ions promote the inactive configuration\" is rather speculative from the two reasons in the following.*

*A) There are no direct evidence which shows PO~4~^3-^ promotes the inactivated conformation. The authors showed mutants of the PO~4~^3-^ binding sites have lower IP accumulation in response to extracellular Ca^2+^. I think the data are not sufficient. To demonstrate the inhibitory effect of PO~4~^3-^ on the response of CaSR to extracellular Ca^2+^ conclusively, I would like to request to present data comparing the responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of PO~4~^3-^, in wt and mutants of the anion binding sites. The expected result is lower response to Ca^2+^ in the presence of PO~4~^3-^ than in the absence, not in mutants but in wt.*

Following the referee's suggestion, we have measured the response of CaSR to extracellular Ca^2+^ in the absence and presence of the anion SO~4~^2-^. We chose SO~4~^2-^ to substitute for PO~4~^3-^ because CaSO~4~ is more soluble than CaHPO~4~, the predominant form of calcium phosphate salt at physiological pH. At pH 7.4, approximately 61.3% of the phosphate ions exist in the form of HPO~4~^2-^ and 38.7% are in the form of H~2~PO~4~^-^. The solubility of CaHPO~4~ and Ca(H~2~PO~4)2~ are 1.5 mM and 71 mM, respectively. The solubility of CaSO~4~ is 15 mM.

As predicted by the referee, and consistent with our structural observation, we found that the response of CaSR to Ca^2+^ was slightly lower in the presence of than in the absence SO~4~^2-^. This confirms that anions have a negative allosteric effect on the receptor. The new data are presented in [Figure 8C](#fig8){ref-type="fig"}.

We have also examined the effects of SO~4~^2-^ on mutants of the anion binding-sites. Our structures revealed that the anion-binding residues R62 at site 1 and R66 at site 3 form hydrogen bonds across the interdomain cleft in the absence of bound anions to stabilize the closed conformation of the receptor. We found that the effect of SO~4~^2-^ on Ca^2+^-induced activation of the R62M mutant was similar to that of the wild-type receptor, while the presence of SO~4~^2-^ had little effect on the activity of the R66H mutant. However, we cannot conclude which anion-binding sites are involved in mediating the inhibitory effect of anions because these mutations are expected to have both positive and negative effects on the receptor function.

A\) The mutations R62M and R66H are expected to eliminate the inhibitory effect of anions by preventing their binding to the receptor.

B\) These same mutations would also disrupt the formation of hydrogen bonds across the interdomain cleft by R62 and R66, thereby eliminating the interactions that favor receptor activation.

Residue R66 is involved in the binding of anion at both sites 2 and 3. Since anion-binding site 2 appears to be crucial for structural integrity of the receptor, disruption of this site by the R66H mutation would negatively affect receptor function.

B\) The authors assume that the electron density represents the presence of PO~4~^3-^ or SO~4~^3-^, because there are no anions in the crystallization solution other than PO~4~^3-^ or SO~4~^3-^. Is there a possibility that carryover endogenous anion(s) other than PO~4~^3-^ is bound to the anion binding site? (similarly to the case of the putative carryover of endogenous amino acid(s) at the L-tryptophan binding site when crystalized in the absence of L-tryptophan).

We agree with the referee that it is possible carryover endogenous anion(s) other than PO~43-~ or SO~42-~ is bound at the anion-binding sites. We have added a sentence in the text to mention the caveat.

*2) Experiments to demonstrate the potentiating effect of L-tryptophan*

I have similar comments to the case of anion effect. To demonstrate the potentiating effect of L-tryptophan on the response of CaSR to extracellular Ca^2+^ conclusively, please present data comparing the responses (IP accumulation) to extracellular Ca^2+^ in the presence and absence of L-tryptophan, in wt and mutants of the L-tryptophan binding sites. The expected result is higher response to Ca^2+^ in the presence of L-tryptophan than in the absence, not in mutants but in wt.

Following the referee's suggestion, we have measured the potentiating effect of L-Trp on the response of wild-type CaSR to extracellular Ca^2+^. As predicted by the referee, Ca^2+^-induced receptor activation is higher in the presence of L-Trp than in the absence. The new data are presented in [Figure 4G](#fig4){ref-type="fig"}.

We have shown using IP accumulation measurements that most alanine mutants of the L-Trp- binding site abolished Ca^2+^-dependent receptor response in the absence of any amino acid. Therefore, these mutants would not be suitable for the study of the L-Trp effect. For the two mutants that displayed partial receptor activity (S147A and Y218S), we found that they did not respond to 10 mM L-Trp in the presence of 2 mM extracellular Ca^2+^.

*3) Comparison with the mGluR and GABABR*

*The authors discussed differences and similarities of the CaSR structure to those of mGluR and GABABR. However, it is hard to follow the explanations in the text, without structure images for comparison.*

*A) The authors mentioned the degree of rotational change of two LB1 interface in CaSR with GABAB and mGluR upon activation (subsection "Common protomer-protomer interactions", third paragraph). In [Figure 3---figure supplement 1 B, D](#fig3s1){ref-type="fig"}, the authors showed two images of CaSR in the resting and activated states. I would like to request to add similar images in the two states of mGluR and GABABR in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, to clarify the discussion of the rotated angle of LB1 interface.*

Following the referee's recommendation, we have added images of the two states of mGluR1 and GABAB receptor comparing the rotated angle of the LB1-LB1 interface in each receptor system ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

B\) The authors described an overall similarity of VFT cleft structure of CaSR and mGluR. They also wrote the tryptophan binding site of CaSR corresponds to the glutamate binding site of mGluR (subsection "Structure of CaSR ECD homodimer", second paragraph). To clarify these points, please present a superimposed image of the VFT cleft of CaSR and mGluR, in e.g. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

We agree with the referee and have added a superimposed image of the agonist-binding cleft of CaSR and mGluR1 in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

*4) Gd3+ binding site*

In the crystal structure of mGluR1, a binding site for Gd3+ was identified at the dimer interface (Tsuchiya et al., PNAS 2002). I would like to have explanations whether or not a similar structure was identified in CaSR.

We think the referee's question is very interesting, and have superimposed the structures of CaSR and mGluR to compare this region of the dimer interface. As shown in [Author response image 3](#fig12){ref-type="fig"}, the Gd^3+^ ion in the mGluR1 structure is coordinated by two acid residues, E238 and D242 from each subunit. The corresponding residues in the CaSR structure are R220 and E224. The basic residue R220 would not be compatible with the binding of a cation to CaSR at this location.10.7554/eLife.13662.025Author response image 3.Superposition of the CaSR and mGluR1 structures in the region of the Gd^3+^-binding site in mGluR1 structure.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.025](10.7554/eLife.13662.025)

Reviewer \#3:

*Geng et al. reported the crystal structures of entire extracellular domain of calcium sensing receptor of calcium free form and loaded forms in the presence of calcium and PO43- ions. This work is of importance for providing insights for the activation mechanism via dimer interface between subunits. There are several major concerns that need be addressed:*

*1) The crystal structures were determined for CaSR with mutations of either two (N386Q and S402N) or three (N468Q) N-glycosylation sites. However, no study has been carried out on the effects of these mutations on expression and function of CaSR. It is important to provide evidence with experimental data that mutations at these glycosylation sites do not result in alteration of the function and expression.*

We agree with the referee that it is important to provide evidence that the glycosylation mutations introduced into our expression constructs do not alter the function of the receptor. It has been reported previously that glycosylation is not required for signal transduction of CaSR (Ray et al., JBC, 1998, 273, 34558-34567). Following the referee's suggestion, we have also generated two full-length CaSR constructs for functional analysis in mammalian cells, one carrying the two glycosylation-site mutations N386Q and S402N, and the other carrying the additional mutation N468Q. We found that Ca^2+^-induced IP accumulation was statistically the same for the wild-type and mutant receptors, indicating that these glycosylation mutations did not alter CaSR function ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

On the other hand, previous studies of full-length CaSR in mammalian cells indicate that disruption of the glycosylation sites impairs proper processing and expression of the receptor at the cell surface (Ray et al., JBC, 1998, 273, 34558-34567). In agreement with these findings, we found that expression of CaSR ECD in insect cells was essentially eliminated when more than three glycosylation sites were mutated. After testing mutations at each of the potential N-linked glycosylation sites individually and in various combinations, we chose the constructs reported in this study to maximize the reduction of carbohydrate content while maintaining a sufficient expression level for structural analyses.

*2) Since mutations could lead to reduction in cell surface expression due to trafficking, it is encouraged to provide confocal images to ensure that the observed change in intracellular IP activity is not due to reduction of protein expression levels on cell surface.*

We appreciate the referee's suggestion. Unfortunately, we do not have any experience with confocal imaging. We did measure the cell surface expression levels of wild-type and mutant CaSR by on-cell western analysis, which was described in the Methods section. Most of the mutants in our study were expressed on the cell surface at levels comparable to that of the wild- type receptor. The exceptions were R66H, R69E, I81M, T100I, N102I, and S417L, which reduced the surface expression of the mutant receptors to approximately 70-75% of the wild-type level. Nevertheless, the reduction in the protein expression level on cell surface could not account for the much greater decrease in intracellular IP accumulation for each of these mutants. We therefore concluded that the mutations affected receptor function.

*3) The identification of Trp binding site is very important for the activation mechanism. It will be very helpful to report Trp binding affinity of the ECD of CaSR.*

We agree with the referee, and have determined the binding affinity of L-Trp for CaSR ECD by scintillation proximity assay using radiolabeled \[^3^H\]-Trp. In the absence of Ca^2+^, the binding of \[^3^H\]-L-Trp to CaSR ECD was inhibited by nonradioactive L-Trp with a half-maximal inhibitory concentration (IC~50~) of 2.1 ± 0.7 mM. The presence of 2 mM Ca^2+^ did not affect the binding affinity of L-Trp, indicating that Ca^2+^ ion is not directly involved in L-Trp recognition. This is consistent with our structural observation that no Ca^2+^ ion is found at the L-Trp-binding site. Nevertheless, Ca^2+^ ion increased the amount of L-Trp bound to CaSR ECD at any given concentration, indicating that extracellular Ca^2+^ enhances the L-Trp-binding site occupancy, possibly by stabilizing the L-Trp-bound and active conformation of CaSR.

*4) Extremely high concentrations of three different anion ions were used for crystallization. The role of anion binding is not clear and some of them appear to be non-specific. Among 4 anion-binding sites identified, sites 1-3 are in inactive form crystalized with 3.0 M Li2SO4, 100 mM Tris pH8.5 with mutations N386Q and S402N. Under this condition, SO42- ions are assigned. On the other hand, 1.6 M NaH2PO4, 0.4 M K2HPO4, 100 mM Na2HPO4/citric acid pH4.2, 10 mM Trp 10 mM Ca^2+^ are used for identification of anion sites in the active form of CaSR with three glycosylation mutations. Thus, 2 anion binding sites were modeled to be PO43-. What is the binding affinity for these anion ions?*

We agree with the referee that it would be informative to determine the binding affinities of the anions to CaSR. We tried to quantify the binding of PO~43-~ ions to purified CaSR ECD protein using microscale thermophoresis, but were unsuccessful. Several factors may have contributed to the difficulties we encountered. (1) The anions at different sites may have overlapping binding affinity ranges that cannot be easily differentiated. (2) Some sites such as site 2 may already be occupied by endogenous anions. (3) Low-affinity anion-receptor interactions at some sites are difficult to detect.

*5) The four calcium binding sites shown in [Figure 5](#fig5){ref-type="fig"} either have incomplete coordination or lack of negatively charged residues. These properties are very different from classical calcium binding sites with at least three ligand oxygen atoms from the protein and with electrostatic interactions. The reported site 3 calcium is directly chelated only by one oxygen from hydroxyl side chin of S302. Site 4 is formed by side chain of D234 and mainchain carbonyl oxygen from E231 and G557. How the function results provided in [Figure 6](#fig6){ref-type="fig"} is a mutation G55E that results in a significantly increase of EC50 for IP accumulation and intracellular calcium response. Why have such big alteration of activity for a replacement of another carbonyl oxygen? Since calcium interaction is largely electrostatic, it would make sense to test the mutational effect D234A.*

We appreciate the referee's observation that the coordination of Ca^2+^ ions at all four binding sites in CaSR appear different from classical Ca^2+^-binding sites. It is possible that water molecules play a role in coordinating the bound Ca^2+^ ions, but could not all be seen in the structures due to disordering or the modest resolution of the structures.

The alteration in receptor activity of the G557E mutant may have resulted from a change in the conformation of the loop containing residue 557 such that the carbonyl oxygen is no longer optimally positioned to coordinate the binding of a Ca^2+^ ion at this site. Nevertheless, the effect of the G557E mutation is not as substantial as some of the other Ca^2+^-binding site mutations including I81M, T100I and N102I, which nearly abolished Ca^2+^-induced receptor activation. The EC~50~ for Ca^2+^-induced IP accumulation increased approximately two fold from 1.6 mM for the wild-type receptor to 3.4 mM for the G557E mutant, while the Emax of the receptor response remained essentially the same.

Following the referee's suggestion, we have tested the mutation D234A, and found that its effect on receptor activity was negligible, as shown by the IP accumulation dose response curves for wild-type receptor and the D234A mutant ([Author response image 4](#fig13){ref-type="fig"}). This may be due to the fact that the side chain of D234 is somewhat flexible, and does not contribute to the binding of Ca^2+^ ion at site 4 as much as the backbone carbonyl oxygen atoms of E231 and G557.10.7554/eLife.13662.026Author response image 4.Dose-dependent Ca^2+^-stimulated IP accumulation in cells transiently expressing the D234A mutant CaSR.**DOI:** [http://dx.doi.org/10.7554/eLife.13662.026](10.7554/eLife.13662.026)

*The provided mutational studies of I181 m, T100I, and N102I all have significantly reduced maximal amplitudes in both IP and intracellular calcium activities in addition to increased EC50. These results suggest that the surface expression of the mutated protein variants are largely reduced. Thus, the effect for these residues in calcium binding cannot be unambiguously revealed. It is important to provide the results for the mutational effect of these identified ligand residues on direct calcium binding affinity.*

The cell surface expression levels of the mutants I81M, T100I, N102I were approximately 70- 75% of the wild-type level based on on-cell western measurements. However, each of these mutations nearly abolished Ca^2+^-dependent receptor response, indicating that their effects on calcium binding and receptor function could not be explained by the reduction in cell surface expression alone.

We agree with the referee that it would be very informative to measure the direct binding affinity of Ca^2+^ at each site, and the mutational effects of Ca^2+^-binding residues. We tried two different approaches to determine the Ca^2+^-binding affinity to wild-type CaSR ECD, including microscale thermophoresis and scintillation proximity assay. Unfortunately, we were not successful possibly for the same reasons that we had difficulties measuring the affinities of anions. (1) The Ca^2+^ ions at different sites may have overlapping binding affinity ranges that cannot be easily differentiated. (2) Some sites such as site 2 may already be occupied by endogenous Ca^2+^. (3) Low-affinity Ca^2+^-receptor interactions at some sites are difficult to detect.

*6) It is worth to pointing out that at pH4.2 sidechain of Asp and Glu are largely protonated with significantly reduced calcium binding capability. In addition, due to poor solubility of calcium phosphate, the molar phosphate concentrations used in the buffer will result in extremely low concentration of soluble free calcium. Thus, the role of calcium binding in activation revealed in the determined structures is likely to be under estimated due to the condition used for crystallization.*

We think the referee raised an important question. However, we do not think that the role of calcium binding in activation as revealed by the determined structures is likely to be underestimated for two reasons.

1\) Based on the following calculation, the proton concentration at pH4.2 is approximately 0.1 mM, much lower than the concentration of free Ca^2+^ (10 mM). Therefore, we think it is more likely for the sidechains of Asp and Glu residues to be bound to Ca^2+^ ion than protonated.

pH = -log\[H^+^\] = 4.2

\[H^+^\] = 1 x 10^-4.2^ M ≈ 0.1 mM

2\) We think the concentration of soluble free calcium under the pH 4.2 crystallization condition should remain at 10 mM because most of the phosphate ions are in the form of H~2~PO~4~^-^, and the solubility of Ca(H~2~PO~4)2~ is approximately 71 mM.

Three equilibrium reactions exist between H~3~PO~4~, H~2~PO~4~^-^, HPO~4~^2-^, and PO~4~^3-^

EquilibriumConstantValueEquilibriumK~a1~7.5 x 10^-3^H~3~PO~4~ \<\--\> H^+^ + H~2~PO~4~^-^K~a2~6.2 x 10^-8^H~2~PO~4~^-^ \<\--\> H^+^ + HPO~4~^2-^K~a3~4.8 x 10^-13^HPO~4~^2-^ \<\--\> H^+^ + PO~4~^3-^

H~3~PO~4~ \<\--\> H^+^ + H~2~PO~4~^-^

pK~a1~ = pH - log(\[H~2~PO~4~^-^\]/\[H~3~PO~4~\])

-log(7.5 x 10^-3^) = 4.2 - log(\[H~2~PO~4~^-^\]/\[H~3~PO~4~\])

\[H~2~PO~4~^-^\]/\[H~3~PO~4~\] = 10^2.1^

H~2~PO~4~^-^ \<\--\> H^+^ + HPO~4~^2-^

pK~a2~ = pH - log(\[HPO~4~^2-^\]/\[H~2~PO~4~^-^\])

-log(6.2 x 10^-8^) = 4.2 - log(\[HPO~4~^2-^\]/\[H~2~PO~4~^-^\])

\[H~2~PO~4~^-^\]/\[HPO~4~^2-^\] = 10^3^

HPO~4~^2-^ \<\--\> H^+^ + PO~4~^3-^

pK~a3~ = pH - log(\[PO~4~^3-^\]/\[HPO~4~^2-^\])

-log(4.8 x 10^-13^) = 4.2 - log(\[PO~4~^3-^\]/\[HPO~4~^2-^\])

\[HPO~4~^2-^\]/\[PO~4~^3-^\] = 10^8.1^

\[H~2~PO~4~^-^\]/\[PO~4~^3-^\] = 10^11.1^

Therefore, more than 99% of the phosphate ions exist in the form of H~2~PO~4~^-^ at pH4.2.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*Thank you for resubmitting your work entitled \"Structural mechanism of ligand activation in human calcium-sensing receptor\" for further consideration at eLife. Your revised article has been favorably evaluated by Randy Schekman (Senior Editor), a Reviewing Editor, and one reviewer.*

*The manuscript has been improved but there is a remaining issue that needs to be addressed before acceptance, as outlined below:*

*1) In the point by point response to Reviewer \#3, comment \#3, the authors stated the following:*

*\"The presence of 2 mM Ca^2+^ did not affect the binding affinity of L-Trp, indicating that Ca^2+^ ion is not directly involved in L-Trp recognition. This is consistent with our structural observation that no Ca^2+^ ion is found at the L-Trp-binding site. Nevertheless, Ca^2+^ ion increased the amount of L-Trp bound to CaSR ECD at any given concentration, indicating that extracellular Ca^2+^ enhances the L-Trp-binding site occupancy, possibly by stabilizing the L-Trp-bound and active conformation of CaSR.\"*

*The authors should clarify what they mean by this. If calcium stabilized the Trp-bound state it would presumably be seen as an increase in Trp affinity. An increase in amount of radio-Trp that is bound that does not shift the affinity curve would seem to suggest adding to circulation Trp binding sites (i.e. receptors) that were previously not available (from an unavailable/inactive pool?). Or is there another possible explanation? Or does this raise a caveat about the experiment? This should be addressed in the text.*

We think referee \#3 has raised a valid criticism. As pointed out by referee \#1 below, we cannot conclude based on our \[^3^H\]-L-Trp binding competition studies alone that the binding affinity of L-Trp is the same with or without Ca^2+^. Given our structural observation that Ca^2+^ stabilizes the active conformation of the receptor, we agree that Ca^2+^ would most likely enhance the binding affinity of L-Trp since the interaction of L-Trp with an active receptor is expected to be more extensive than with an inactive receptor. In an active receptor, L-Trp would contact both the LB1 and LB2 domains. L-Trp may still bind to the open cleft in an inactive receptor, but its interaction with the receptor will be limited to the LB1 domain, which would result in lower affinity. The binding of glutamate to an open cleft has previously been observed for mGluR1 (Kunishima et al., Nature 2000, 407, 971-977).

Unfortunately, as indicated by referee \#1, it would be difficult for us to measure the binding affinity of L-Trp in a saturation binding experiment since the concentration of \[^3^H\]-L-Trp required would be ≥10 mM, and a relatively low specific radioactivity of the commercially available radio-labeled ligand may preclude such experiments. Our competition experiments in the current study were performed at 0.1 mM \[^3^H\]-L-Trp, a concentration that is about 20-fold below the determined half-maximal inhibitory concentration (IC~50~) of non-labeled L-Trp for replacing radiolabeled L-Trp.

In addition, the presence of Ca^2+^ may affect the on- and off-rate of L-Trp binding to CaSR ECD. Specifically, L-Trp may have a slower off-rate when bound to the active conformation. Therefore, the higher amount of L-Trp binding observed with Ca^2+^ may reflect the different L-Trp binding affinity and kinetics exhibited by the inactive and active receptors. We have modified our text to include these explanations and to indicate that additional studies would be needed to characterize the role of L-amino acid binding to the orthosteric agonist site of CaSR.

[^1]: Values in parentheses are for highest-resolution shell.

[^2]: CC~1/2~ is defined in reference ([@bib31]).
